

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

Psychosocial factors at work and inflammatory markers: protocol for a systematic review and meta-analysis

Journal:	BMJ Open
Manuscript ID	bmjopen-2018-022612
Article Type:	Protocol
Date Submitted by the Author:	02-Mar-2018
Complete List of Authors:	Eguchi, Hisashi; Kitasato University School of Medicine, Department of Public Health Watanabe, Kazuhiro; The University of Tokyo, Department of Mental Health, Graduate School of Medicine Kawakami, Norito; The University of Tokyo, Department of Mental Health Ando, Emiko; Osaka University, Department of Social and Environmental Health, Division of Environmental Medicine and Population Sciences, Graduate School of Medicine Arima, Hideaki; The University of Tokyo, Department of Mental Health, Graduate School of Medicine Asai, Yumi; The University of Tokyo, Department of Mental Health, Graduate School of Medicine Inoue, Akiomi; Kitasato University School of Medicine, Department of Public Health Inoue, Reiko; Hitachi Automotive Systems Ltd Iwanaga, Mai; Graduate School of Medicine, The university of Tokyo, Department of Psychiatric Nursing Imamura, Kotaro; The University of Tokyo, Department of Mental Health, Graduate School of Medicine Kobayashi, Yuka; Honda Motor Co., Ltd. Nishida, Norimitsu; Kyoto Industrial Health Association Otsuka, Yasumasa; Faculty of Human Sciences, University of Tsukuba Sakuraya, Asuka; The University of Tokyo, Department of Mental Health, Graduate School of Medicine Tsuno, Kanami; Wakayama Medical University - Kimiidera Campus, Department of Hygiene, School of Medicine Shimazu, Akihito; College of Liberal Arts and Sciences, Kitasato University, Tsutsum, Akizumi; Kitasato University, Department of Public Health
Keywords:	Inflammation, Psychosocial factors at work, Cardiology < INTERNAL MEDICINE, Occupational health, Workplace, MENTAL HEALTH

SCHOLARONE[™] Manuscripts

1		
2		
3 1		
4 5	1	Psychosocial factors at work and inflammatory markers, protocol for a
6	1	
7	2	systematic review and meta-analysis
8	3	
9 10	4	Authors
10	5	Hisashi Eguchi ^{1*} , Kazuhiro Watanabe ^{2,3*} , Norito Kawakami ² , Emiko Ando ⁴ ,
12	6	Hideaki Arima ² , Yumi Asai ² , Akiomi Inoue ¹ , Reiko Inoue ⁵ , Mai Iwanaga ⁶ , Kotaro
13	7	Imamura ² Vuka Kobavashi ⁷ Norimitsu Nishida ⁸ Vasumasa Otsuka ⁹ Asuka
14	•	S_{2} K_{2} K_{2
16	8	Sakulaya, Kahanin Isuno, Akinito Shinazu, Akizumi Isutsumi
17	9	1-
18	10	'Department of Public Health, Kitasato University School of Medicine,
19 20	11	Sgamihara, Japan
20	12	² Department of Mental Health, Graduate School of Medicine, The University of
22	13	Tokyo, Tokyo, Japan
23	14	³ The Japan Society for the Promotion of Science, Tokyo, Japan
24 25	15	⁴ Division of Environmental Medicine and Population Sciences. Department of
25	10	Casial and Environmental Medicine, Creducta Cabaal of Medicine, Ocalia
27	16	
28	17	University, Osaka, Japan
29 30	18	⁵ Hitachi Automotive Systems, Ltd., Hitachinaka, Japan
30	19	⁶ Department of Psychiatric Nursing, Graduate School of Medicine, The
32	20	University of Tokyo, Tokyo, Japan
33	21	⁷ Honda Motor Co., Ltd., Tokyo, Japan
34 35	22	⁸ Kvoto Industrial Health Association, Kvoto, Japan
36	23	⁹ Faculty of Human Sciences, University of Tsukuba, Tokyo, Japan
37	20	¹⁰ Department of Hygione, School of Medicine, Wakayama Medical University
38	24	Melanama lanar
39 40	25	Wakayama, Japan
41	26	"Center for Human and Sciences, College of Liberal Arts and Sciences,
42	27	Kitasato University, Sagamihara, Japan
43	28	*HE and KW made equal contributions to this study.
44 45	29	
46	30	Corresponding author
47	31	Akizumi Tsutsumi
48 40	20	Department of Public Health, Kitasata University School of Medicine, Japan
49 50	32	1 15 1 Kitaasta Minami ku Casamihara ahi Kanamawa 050 0071 Janan
51	33	I-IJ-I Kitasato, iviinami-ku, Sagaminara-sni, Kanagawa, 252-0374, Japan
52	34	Email address: akizumi@kitasato-u.ac.jp
53 54	35	Phone: +81-42-778-9352
54 55	36	Fax: +81-42-778-9257
56		
57		
58 50		
27		

2		
3 4		
5	37	
6	38	Word count: 1 819 words
7	00	
9		
10		
11		
12		
14		
15		
16		
18		
19		
20		
22		
23		
24		
26		
27		
29		
30		
31 32		
33		
34		
35 36		
37		
38		
39 40		
41		
42		
43 44		
45		
46 47		
48		
49		
50 51		
52		
53		
54 55		
56		
57		
58 59		
.17		

39	Strengths and limitations of this study
40	This systematic review and meta-analysis will offer comprehensive
41	understanding of the association between work-related psychosocial factors
42	and inflammatory markers.
43	
44	 The review will include a range of work-related psychosocial factors, and
45	focus on inflammatory markers as an aggregated cluster.
46	
47	 The review will only include prospective studies to ensure stronger evidence.
48	• The findings of this review may be useful for essential abranic inflormation
49 50	 The findings of this review may be useful for assessing chronic inflammation as a risk factor for cardiovascular disease (CVD) in the workplace, and
50 51	determining future approaches for CVD prevention
52	
53	• Depending on the results, limitations may be confounding factors that might
54	not have been adjusted for in the selected studies and low generalizability.

55 Abstract

INTRODUCTION: Chronic inflammation may be a mediator for the development of cardiovascular disease (CVD). Meta-analytic associations between work-related psychosocial factors and inflammatory markers have shown that work-related psychosocial factors may affect the flexibility and balance of the immune system. However, few systematic reviews or meta-analyses have investigated the association between work-related psychosocial factors and inflammatory markers. This study aims to conduct a comprehensive systematic review and meta-analysis of the effects of work-related psychosocial factors on inflammatory markers, based on prospective studies.

METHODS AND ANALYSIS: The systematic review and meta-analysis will
 include published studies identified from electronic databases (PubMed,
 EMBASE, PsycINFO, PsycARTICLES, and Japan Medical Abstracts Society)
 according to the recommendations of the Meta-analysis of Observational

- 69 Studies in Epidemiology guideline. Inclusion criteria are studies that: examined
- 70 associations between work-related psychosocial factors and increased
- inflammatory markers; used longitudinal or prospective cohort designs; were
- 72 conducted among workers; provided sufficient data for calculating odds ratios or
- relative risk with 95% confidence intervals; were published as original articles in
- Figure 74 English or Japanese; and were published up to the end of 2017. Study selection,

data collection, quality assessment, and statistical syntheses will be conducted
 based on discussions among investigators.

- 77 ETHICS AND DISSEMINATION: This study is based on published studies,
- 78 meaning ethics approval is not required. The results of this study will be
- ⁷⁹ submitted for publication in a scientific peer-reviewed journal. The findings may
- 80 be useful for assessing risk factors for increased inflammatory markers in the
- 81 workplace and determining future approaches for CVD prevention.
- TRIAL REGISTRATION NUMBER: PROSPERO CRD42018081553
- 83 (https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=81553).

1	
2	
3 ⊿	
5	
6	
7	
8 9	
10	
11	
12	
14	
15	
16	
17	
19	
20	
21	
23	
24	
25 26	
27	
28	
29 30	
31	
32	
33 34	
35	
36	
37 38	
39	
40	
41 42	
43	
44	
45 46	
40 47	
48	
49 50	
50	
52	
53	
54 55	
56	
57	
58 59	
60	

84 Introduction

85 Most adults spend around half of their waking hours at work, meaning the workplace is an important setting to promote health and wellbeing. 86 87 Increasing attention is being directed to work-related psychosocial factors, with a 88 major focus on work stress.[1] Work-related psychosocial factors include job strain,[1-5] effort-reward imbalance,[6] organizational justice,[7-9] and workplace 89 social capital.[10] These factors affect cardiovascular disease (CVD) or risk 90 factors for CVD (e.g., body mass index, blood pressure) through mechanisms 91 such as prolonged overactivation and dysregulation of the autonomic nervous 92 system and the hypothalamus-pituitary-adrenal cortex axis.[11-13] 93

94 Chronic inflammation has been suggested as a potential mediator for the 95 development of CVD.[14] Several previous studies reported associations between adverse work-related psychosocial factors and increased levels of 96 97 inflammatory markers. Inflammatory markers, including C-reactive protein (CRP),[15-20] interleukin-6 (IL-6),[20 21] and tumor necrosis factor (TNF- α), are 98 99 implicated in coordinating atherosclerosis.[22] Previous meta-analyses[23,24] 100 identified associations between psychosocial factors and inflammatory markers, 101 but findings from these studies were not stable because of heterogeneity in methods (e.g., the conceptualization or measurement of work-related 102 103 psychosocial factors, sample compositions, and statistical approaches).

104 Meta-analytic associations between work-related psychosocial factors 105 and inflammatory markers indicate work-related psychosocial factors may affect the flexibility and balance of the immune system. Although some meta-analyses 106 107 investigated inflammatory markers in relation to psychological stress[23-26] and unemployment, [27] few systematic reviews or meta-analysis have been 108 conducted regarding the associations between work-related psychosocial 109 factors and inflammatory markers. A previous systematic review of 56 studies by 110 Nakata[28] suggested that work-related psychosocial factors were related to 111 112 disrupted immune response. However, that study did not statistically synthesize 113 the associations. To our knowledge, only one meta-analysis of the association between effort-reward imbalance and inflammatory markers (k=7, N=9952) 114 found a negative association with immunity (r=-0.09, confidence interval [CI]: 115 -0.14, -0.05; p<0.001).[13] These previous systematic reviews and</p> 116 meta-analyses included cross-sectional studies. However, pooled associations 117 between work-related psychosocial factors and inflammatory markers derived 118 from prospective studies may provide more reliable evidence. 119

This study aims to conduct a comprehensive systematic review and meta-analysis of the effects of work-related psychosocial factors on inflammatory markers, based on published prospective studies. Our hypothesis is that adverse work-related psychosocial factors would increase inflammatory markers. Moreover, we will identify the work-related psychological factors that have the strongest associations with specific inflammatory markers.

127 Methods and analysis

128 Study design

This study protocol for a systematic review and meta-analysis of prospective studies follows the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols guideline.[29] Future findings will be reported according to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guidelines.[30] This study protocol was registered with PROSPERO (CRD42018081553).

136 Eligibility criteria

Participants, exposures, comparisons, and outcomes (PECO) of the studies included in this systematic review and meta-analysis will be defined as follows: (P) inclusion of all workers, (E) presence of adverse psychosocial factors at work, (C) absence of adverse psychosocial factors at work, and (O) increased inflammatory markers. Target participants are all employed workers of participating companies. There will be no exclusion criteria related to employment status, job type, and shift type. The study exposures (adverse psychosocial factors at work) will include a range of task and organizational characteristics, work conditions, and workplace interactions, [31] including job strain, low social support, effort-reward imbalance, organizational injustice, and low workplace social capital. Long working hours and shift work will also be included as target exposures. Inflammatory markers will include those that were investigated in terms of associations with psychosocial factors at work in previous studies, including CRP, IL-6, and TNF- α .

Eligibility criteria for study selection are studies that: 1) were conducted to evaluate associations between psychosocial factors at work and inflammatory markers; 2) used longitudinal or prospective cohort designs; 3) were conducted among workers; 4) provided sufficient data for calculating coefficients between psychosocial factors at work and inflammatory markers (γ , β), odds ratios (ORs),

1		
2		
4		
5	156	relative risks (RRs), or hazard ratios (HRs) with standard errors (SEs) or 95%
6	157	Cls; 5) were published as original articles in English or Japanese; and 6) were
8	158	published up to the end of 2017.
9	159	
10 11	160	Information sources search strategy and data management
12	161	A systematic search of published studies will be conducted using
13	162	electronic databases: PubMed (MEDLINE) EMBASE
14 15	163	PsycINEO/PsycABTICLES and the Japan Medical Abstracts Society Search
16	164	torma will include words related to the PECO of aligible published studies. The
17	164	terms will include words related to the PECO of engible published studies. The
18 10	165	proposed search strategy is snown in Appendix 1. All identified studies will be
20	166	managed in a Microsoft [®] Excel file (Washington, US). Before the study selection
21	167	process, duplicated citations in the Excel file will be excluded by KW. Decisions
22	168	on all studies will be recorded.
23	169	
25	170	Study selection process
26	171	First, 14 investigators (HE, KW, EA, HA, YA, AI, RI, MI, KI, YK, NN, YO,
27 28	172	ASa, and KT) will independently conduct screening of identified titles and
29	173	abstracts, according to the eligibility criteria. Second, we will obtain full texts of
30	174	all eligible studies. In the full text review phase, the studies will be reviewed
32	175	using a standardized form for assessing eligibility for inclusion in this review. Any
33	176	disagreements will be settled in discussion among all authors until consensus is
34 35	177	reached. We will directly contact corresponding authors of eligible studies if the
36	178	results of the publication are unclear and may be related to multiple
37	179	interpretations, or the results reported in the publication did not show data
38 39	190	relevant to our study analysis. The reasons for excluding studies will be recorded
40	100	A flow obert will be prepared that above the aptire review process.
41	181	A now chart will be prepared that shows the entire review process.
42 43	182	
43	183	Data collection
45	184	Data will be extracted independently from the included studies by 14
46	185	investigators (HE, KW, EA, HA, YA, AI, RI, MI, KI, YK, NN, YO, ASa, and KT)
47	186	using a standardized data extraction form. Any disagreement or inconsistencies
49	187	will be resolved by consultation and consensus among all authors. Collected
50	188	data will include: year of publication, country where the study was conducted,
51 52	189	numbers of participants included at baseline and in the analysis, sampling
53	190	framework, participants' demographic characteristics (i.e., mean age, sex
54	191	proportions, and employment status), length of follow-up, follow-up rate.
55	191	proportions, and employment status), length of follow-up, follow-up rate,

exposure and comparison variables (adverse psychosocial factors at work), outcome variables (inflammatory markers), number and proportion of participants with increased levels of inflammatory markers or mean scores and variances/standard deviations of markers, and sufficient data for calculating the coefficients (β , γ), ORs, RRs, or HRs with SEs/95% CIs for the association between adverse psychosocial factors at work and inflammatory markers. When the included studies report multiple measures of association, we will preferentially select measures of association adjusted by demographic (e.g., age, sex, education, and marital status) and lifestyle variables (e.g., smoking, physical activity, and sleep). Measures of association adjusted for other adverse psychosocial factors at work and/or inflammatory markers will not be adopted to avoid over-adjustment. Sex-stratified coefficients will be selected if those were the only reported results. Any missing data from the studies will be obtained by contacting the relevant research team.

207 Assessment of study quality

Fourteen investigators (HE, KW, EA, HA, YA, AI, RI, MI, KI, YK, NN, YO, ASa, and KT) will independently assess the quality of each included study using the Newcastle-Ottawa Quality Assessment Scale (NOS).[32] The NOS evaluates cohort studies based on eight items categorized into three groups: 1) selection of study cases, 2) comparability of the population, and 3) ascertainment of whether the exposures or outcomes included any risk of bias (i.e., selection bias or bias from loss to follow-up). NOS scores range from 0-9, with studies scoring \geq 7 considered high quality.[33] Discrepancies in quality assessment among investigators will be resolved by discussion and consensus among all authors.

219 Data synthesis and statistical methods

The included studies will be statistically synthesized in a meta-analysis to estimate pooled coefficients and 95% CIs, stratified by the types of measures of association (β , γ , OR, RR, and HR). When the included studies report ORs, RRs, or HRs, we will calculate log-transformed ORs, RRs, or HRs, and estimate SEs based on 95% CIs. These parameters will be used in the meta-analysis and for examining publication bias using a funnel plot and Egger's test. [34,35] We will use a random effects model[36] to summarize the results using R version 3.4.1 with the "meta" and "metafor" packages.[37] The results will be presented in a

2		
4		
5	228	narrative format if a meta-analysis is not appropriate or possible. Heterogeneity
6 7	229	will be assessed by the chi-square test with Cochran's Q statistic, which is
8	230	calculated by l^2 values,[38] on the assumption that l^2 values of 25%, 50%, and
9 10	231	75% indicate low, medium, and high heterogeneity, respectively.
11	232	Subgroup and sensitivity analyses will also be conducted to compare the
12	233	results across subgroups or under specific conditions when sufficient
13 14	234	heterogeneity is detected. Major grouping characteristics will include types of
15	235	exposures and outcomes, participants' demographic characteristics (e.g., sex,
16 17	236	age, employment status, occupational groups), and study quality. Any subgroup
17	237	differences will be reported, and our findings will be explained by considering
19	238	these differences. When trends are observed between pooled associations and
20 21	239	any grouping characteristics, meta-regression will be conducted using the
22	240	"metareg" function of R. A sensitivity analysis may be conducted for included
23	241	studies with a NOS score indicating high guality (\geq 7). All collected data and
24 25	242	analyzed results will be deposited by the corresponding author and available for
26	243	external reviewers and readers upon request.
27 28	244	
29	245	Patient and Public Involvement statement
30	246	Any patients and or study participants were not involved in this study
31	247	because this is the study protocol for the systematic review and meta-analysis.
33	248	
34 35	249	Ethics and dissemination
36	250	This study does not require ethical approval because the systematic review and
37	251	meta-analysis will be based on previously published studies. The results will be
38 39	252	submitted for publication in a scientific peer-reviewed journal, according to the
40	253	MOOSE quideline.[30]
41 42	254	
43	255	Funding
44	256	This study is supported by the Work-related Diseases Clinical Research Grant
45 46	257	2016 (160701-01) from the Ministry of Health, Labour and Welfare, Japan. The
47	258	funder has no role in study design, data collection and analysis, decision to
48 49	259	publish or preparation of the final manuscript
50	260	
51 52	261	Competing interests
52 53	201	The author(s) declare that they have no competing interests
54	262	The dution (5) decide that they have no competing interests.
55 56	200	
57		
58		
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

264 Strengths and limitations

This systematic review and meta-analysis will be based on prospective studies, and show the strongest evidence for comprehensive associations between psychosocial factors at work and inflammatory markers. The findings will highlight potential mediators and underlying mechanisms for the development of CVD due to adverse psychosocial factors.

There are several likely limitations in this study, including confounding bias and low generalizability. If selected studies do not report demographic-adjusted associations, the findings will be distorted by the unobserved characteristics among the population. In addition, the findings will not be generalizable to populations that were not included in the selected studies.

277 Authors' contributions

HE, KW, NK, EA, HA, YA, AI, RI, MI, KI, YK, NN, YO, ASa, KT, ASh, and AT
made substantial contributions to the conception and design of the study, writing
the protocol and revising it critically for important intellectual content, and
approving the final version to be published. All authors will be involved in the
entire study process (i.e., data collection, assessment, and synthesis).

284 Acknowledgements

We thank Audrey Holmes, MA, from Edanz Group (www.edanzediting.com/ac)
 for editing a draft of this manuscript.

289 References

- Kivimaki M, Kawachi I. Work stress as a risk factor for cardiovascular
 disease. *Curr Cardiol Rep* 2015;17:630. doi: 10.1007/s11886-015-0630-8
- 292 2. Kivimaki M, Nyberg ST, Batty GD, et al. Job strain as a risk factor for
 293 coronary heart disease: a collaborative meta-analysis of individual
- 294 participant data. *Lancet* 2012;380:1491–7.
- doi:10.1016/s0140-6736(12)60994-5
- Fishta A, Backe EM. Psychosocial stress at work and cardiovascular
 diseases: an overview of systematic reviews. *Int Arch Occup Environ Health* 2015;88:997–1014. doi:10.1007/s00420-015-1019-0
- 4. Theorell T, Karasek RA. Current issues relating to psychosocial job strain

3			
4 5	200		and pardiovacoular diagona response / Occup Haalth Povahal 1006:1:0, 26
6	300	_	and cardiovascular disease research. J Occup Health Psychol 1996,1.9–26.
7	301	5.	Belkic KL, Landsbergis PA, Schnall PL, et al. Is job strain a major source of
8	302		cardiovascular disease risk? <i>Scand J Work Environ Health</i> 2004;30:85–128.
9	303	6.	Trudel X, Brisson C, Milot A, et al. Effort-reward imbalance at work and
11	304		5-year changes in blood pressure: the mediating effect of changes in body
12	305		mass index among 1400 white-collar workers. Int Arch Occup Environ
13 14	306		<i>Health</i> 2016:89:1229–38. doi:10.1007/s00420-016-1159-x
15	307	7.	De Vogli R, Ferrie JE, Chandola T, et al. Unfairness and health: evidence
16 17	308		from the Whitehall II Study. J Epidemiol Community Health 2007;61:513–8.
18	309		doi:10.1136/jech.2006.052563
19 20	310	8.	Elovainio M, Leino-Arjas P, Vahtera J, et al. Justice at work and
20	311		cardiovascular mortality: a prospective cohort study. J Psychosom Res
22	312		2006;61:271–4. doi:10.1016/j.jpsychores.2006.02.018
23	313	9.	Kivimaki M, Ferrie JE, Brunner E, et al. Justice at work and reduced risk of
24 25	314		coronary heart disease among employees: the Whitehall II Study. Arch
26	315		Intern Med 2005;165:2245-51. doi:10.1001/archinte.165.19.2245
27 28	316	10.	Oksanen T, Kawachi I, Jokela M, et al. Workplace social capital and risk of
29	317		chronic and severe hypertension: a cohort study. J Hypertens
30 31	318		2012;30:1129–36. doi:10.1097/HJH.0b013e32835377ed
32	319	11.	Kivimaki M, Virtanen M, Elovainio M, et al. Work stress in the etiology of
33 34	320		coronary heart disease—a meta-analysis. Scand J Work Environ Health
35	321		2006;32:431–42.
36 37	322	12.	Barth J, Schneider S, von Kanel R. Lack of social support in the etiology and
38	323		the prognosis of coronary heart disease: a systematic review and
39	324		meta-analysis. Psychosom Med 2010;72:229–38.
40	325		doi:10.1097/PSY.0b013e3181d01611
41	326	13.	Eddy P, Heckenberg R, Wertheim EH, et al. A systematic review and
43	327		meta-analysis of the effort-reward imbalance model of workplace stress with
44 45	328		indicators of immune function. J Psychosom Res 2016;91:1–8.
46	329		doi:10.1016/j.jpsychores.2016.10.003
47 48	330	14.	Lopez-Candales A, Hernandez Burgos PM, Hernandez-Suarez DF, et al.
49	331		Linking chronic inflammation with cardiovascular disease: From normal
50	332		aging to the metabolic syndrome. J Nat Sci 2017;3:e341.
51	333	15.	Eguchi H, Shimazu A, Kawakami N, et al. Source-specific workplace social
53	334		support and high-sensitivity C-reactive protein levels among Japanese
54 55	335		workers: A 1-year prospective cohort study. Am J Ind Med 2016;59:676–84.
56			
57			
58			
60			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2	
3	
4	
-	
Э	
6	
7	
0	
0	
9	
10	
11	
12	
12	
13	
14	
15	
16	
10	
17	
18	
19	
20	
20	
21	
22	
23	
24	
24	
25	
26	
27	
28	
20	
29	
30	
31	
32	
52	
33	
34	
35	
36	
50	
37	
38	
39	
40	
40	
41	
42	
43	
11	
44	
45	
46	
47	
10	
40	
49	
50	
51	
50	
52	
53	
54	
55	
56	
20	
57	
58	
59	
60	

doi:10.	1002/aji	m.22600

- 16. Tsai SS, Lai CH, Shih TS, et al. High job strain is associated with
 inflammatory markers of disease in young long-haul bus drivers. *J Occup Health Psychol* 2014;19:336–47. doi:10.1037/a0036600
- 17. Emeny R, Lacruz ME, Baumert J, et al. Job strain associated CRP is
 mediated by leisure time physical activity: results from the MONICA/KORA
 study. *Brain Behav Immun* 2012;26:1077–84. doi:10.1016/j.bbi.2012.07.004
- 18. Xu W, Chen B, Guo L, et al. High-sensitivity CRP: possible link between job
 stress and atherosclerosis. *Am J Ind Med* 2015;58:773–9.
 doi:10.1002/ajim.22470
- 19. Almadi T, Cathers I, Hamdan Mansour AM, et al. The association between
 work stress and inflammatory biomarkers in Jordanian male workers.
- Psychophysiology 2012;49:172–7. doi:10.1111/j.1469-8986.2011.01296.x
 20. Elovainio M, Ferrie JE, Singh-Manoux A, et al. Organisational justice and
 markers of inflammation: the Whitehall II study. *Occup Environ Med*2010;67:78–83. doi:10.1136/oem.2008.044917
- 21. Nakata A, Irie M, Takahashi M. Source-specific social support and circulating
 inflammatory markers among white-collar employees. *Ann Behav Med* 2014;47:335–46. doi:10.1007/s12160-013-9555-x
- Ridker PM, Luscher TF. Anti-inflammatory therapies for cardiovascular
 disease. *Eur Heart J* 2014;35:1782–91. doi:10.1093/eurheartj/ehu203
- 23. Herbert TB, Cohen S. Stress and immunity in humans: a meta-analytic
 review. *Psychosom Med* 1993;55:364–79.
- Segerstrom SC, Miller GE. Psychological stress and the human immune
 system: a meta-analytic study of 30 years of inquiry. *Psychol Bull* 2004;130:601–30. doi:10.1037/0033-2909.130.4.601
- Steptoe A, Hamer M, Chida Y. The effects of acute psychological stress on
 circulating inflammatory factors in humans: A review and meta-analysis.
 Brain Behav Immun 2007;21:901–12. doi:10.1016/j.bbi.2007.03.011
- 26. Marsland AL, Walsh C, Lockwood K, et al. The effects of acute psychological
 stress on circulating and stimulated inflammatory markers: A systematic
 review and meta-analysis. *Brain Behav Immun* 2017;64:208–19.
 doi:10.1016/j.bbi.2017.01.011
- 369 27. Hughes A, Kumari M, McMunn A, et al. Unemployment and inflammatory
 370 markers in England, Wales and Scotland, 1998–2012: Meta-analysis of
- results from 12 studies. *Brain Behav Immun* 2017;64:91–102.

60

2			
3 4			
5	372		doi:10.1016/j.bbi.2017.03.012
6	373	28.	Nakata A. Psychosocial job stress and immunity: A systematic review. In:
8	374		Yan Q. ed. Psychoneuroimmunology: Methods and protocols. Totowa, NJ:
9	375		Humana Press 2012:39–75
10	376	29	Moher D. Shamseer I. Clarke M. et al. Preferred reporting items for
12	377	20.	systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.
13 14	378		Systematic Reviews 2015;4:1. doi:10.1186/2046-4053-4-1
15	379	30.	Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational
16 17	380		studies in epidemiology: a proposal for reporting. Meta-analysis Of
17	381		Observational Studies in Epidemiology (MOOSE) group. JAMA
19 20	382		2000;283:2008–12.
20	383	31.	Semmer NK. Job stress interventions and the organization of work. <i>Scand J</i>
22	384		Work, Environ Health 2006;32(6):515–27.
23 24	385	32.	Wells G, Shea B, O'connell D. The Newcastle-Ottawa Scale (NOS) for
25	386		assessing the quality of nonrandomized studies in meta-analyses.
26	387		Secondary The Newcastle-Ottawa Scale (NOS) for assessing the quality of
28	388		nonrandomised studies in meta-analyses, 2014. Available from:
29	389		http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
30 31	390	33.	Sun K, Ren M, Liu D, et al. Alcohol consumption and risk of metabolic
32	391		syndrome: a meta-analysis of prospective studies. Clin Nutr 2014;33:596-
33	392		602. doi:10.1016/j.clnu.2013.10.003
34 35	393	34.	Watanabe K, Imamura K, Kawakami N. Working hours and the onset of
36	394		depressive disorder: a systematic review and meta-analysis. Occup Environ
37 38	395		Med 2016;73:877–84. doi:10.1136/oemed-2016-103845
39	396	35.	Sakuraya A, Watanabe K, Kawakami N, et al. Work-related psychosocial
40	397		factors and onset of metabolic syndrome among workers: a systematic
41 42	398		review and meta-analysis protocol. <i>BMJ open</i> 2017;7:e016716.
43	399		doi:10.1136/bmjopen-2017-016716
44 45	400	36.	Hunter JE, Schmidt FL. Fixed effects vs. random effects meta-analysis
45	401		models: Implications for cumulative research knowledge. Int J Sel Assess
47	402		2000;8:275–92. doi:10.1111/1468-2389.00156
48 49	403	37.	Team RC. R: A language and environment for statistical computing. Vienna.
50	404		Austria: R Foundation for Statistical Computing; 2014.
51 52	405	38.	Higgins J. Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat
53	406		<i>Med</i> 2002:21:1539–58.
54	407		,
55 56	_ / .		
57			
58			
59			

Appendix 1. Search terms used for the electronic databases

PubMed(employe*[tw] OR manag*[tw] OR colleague*[tw] OR worksit*[tw] OR "work" [tw] OR works*[tw] OR work* worka*[tw] OR worke*[tw] OR workg*[tw] OR worki*[tw] OR workl*[tw] OR works*[tw] OR works*[
standing[Title/Abstract] OR twisting[Title/Abstract] OR toending[Title/Abstract] OR teaching[Title/Abstract] OR sedentary[Title/Abstract] OR repetitive movement*[Title/Abstract] OR monotonous work[Title/Abstract] OR relaxation[Title/Abstract] OR recovery of function[Title/Abstract] OR physical demand OR physically demand*[Title/Abstract]) OR ("Stress, Psychological"[Majr] OR "Social Support"[Majr] OR "Job Satisfaction"[Mesh] OR "Work Schedule Tolerance"[Mesh] OR "Employee Performance Appraisal"[Mesh] OR " Grievances"[Mesh] OR "Social Justice/psychology"[Mesh] OR "Prejudice"[Mesh] OR "Social Discrimination"[N "Interpersonal Relations"[Mesh] OR "Bullying"[Mesh] OR "Prejudice"[Mesh] OR "Social Discrimination"[N "Interpersonal Relations"[Mesh] OR "Communication/psychology"[Mesh]) OR (psychosocial[Title/Abstract] OR strain[Title/Abstract] OR work strain[Title/Abstract] OR work demand*[Title/Abstract] OR work control[Title/Abstract] OR work control[Title/Abstract] OR work control[Title control[Title/Abstract] OR decision latitude[Title/Abstract] OR work influence*[Title/Abstract] OR demand resource*[Title/Abstract] OR effort reward*[Title/Abstract] OR time pressure*[Title/Abstract] OR coping] OR work overload*[Title/Abstract] OR work over-load*[Title/Abstract] OR recovery[Title/Abstract] OR coping] OR work ability[Title/Abstract] OR emotional support[Title/Abstract] OR interpersonal relation*[Title/Abstract] OR social network*[Title/Abstract] OR emotional support[Title/Abstract] OR interpersonal relation*[Title/Abstract] OR interaction*[Title/Abstract] OR portdom[Title/Abstract] OR interpersonal relation*[Title/Abstract] OR interaction*[Title/Abstract] OR boredom[Title/Abstract] OR isple statif developmenterpersonal	[tw] OR DR company*[tw] g"[Mesh] OR OR sture) OR ct] OR dynamic (Abstract] OR R (Abstract] OR *[Title/Abstract] Employee opment"[Mesh] lesh] OR .job bstract] OR high c/Abstract] OR high bstract] OR high c/Abstract] OR job
OR discrimination[Title/Abstract] OR harass*[Title/Abstract] OR work-place conflict*[Title/Abstract] OR workp	lace

Page 15 of 19

	violen*[Title/Abstract] OR work-place violen*[Title/Abstract] OR bullying[Title/Abstract] OR ageism[Title/Abstract] OR homophobia[Title/Abstract] OR racism[Title/Abstract] OR sexism[Title/Abstract] OR victimization*[Title/Abstract] OR silent workplace*[Title/Abstract] OR role ambiguity[Title/Abstract] OR role-conflict*[Title/Abstract] OR work-role*[Title/Abstract] OR working hour*[Title/Abstract] OR working time[Title/Abstract] OR day-time[Title/Abstract] OR might-time[Title/Abstract] OR shift work*[Title/Abstract] OR work shift*[Title/Abstract] OR temporary work[Title/Abstract] OR full-time[Title/Abstract] OR part-time[Title/Abstract] OR lean production[Title/Abstract] OR job security[Title/Abstract] OR job insecurity[Title/Abstract])) AND (("inflammation"[MeSH Terms] OR inflammation*[All Fields]) OR ("immune system"[MeSH Terms] OR "immune system phenomena"[MeSH Terms] OR "immunity"[All Fields] OR c-reactive protein[All Fields]) OR ("c-reactive protein"[MeSH Terms] OR cytokine*[All Fields]) OR ("upphokines"[MeSH Terms] OR monokine*[All Fields]) OR ("cytokines"[MeSH Terms] OR cytokine*[All Fields]) OR ("immonology"[All Fields] OR CRP[All Fields]) OR ("ctemokines"[MeSH Terms] OR cytokine*[All Fields]) OR ("immonology"[MeSH Terms] OR monokine*[All Fields]) OR ("ctemokines"[MeSH Terms] OR cytokine*[All Fields]) OR ("immonokines"[MeSH Terms] OR monokine*[All Fields]) OR ("tumor necrosis factor-alpha"[MeSH Terms] OR tumor necrosis factor*[All Fields] OR ("tumor"[All Fields]) OR ("tumor necrosis factor*[All Fields]) OR ("tumor"[All Fields]) OR ("tumor"[All Fields]) OR ("tumor"[All Fields]) OR ("interleukins"[MeSH Terms] OR interleukin*[All Fields]) OR ("tumor"[All Fields]] OR ("tumor"[All Fields]) OR ("tumor"[All Fields]) OR ("tumor"[All Fields]) OR ("tumor"[All Fields]) OR ("tumor necrosis factor*[All Fields]) OR ("tumor"[All Fields]) OR (IL[All Fields])) OR (Decover to color to tudy) OR (prospective studies) OR (foll
EMBASE, PsycINFO/ PsycARTICLES	(toightutinal study) OK (prospective conditistudy) OK (prospective studies) OK (notw-up studies) OK (tober valorial study) (employee OR manage OR colleague & OR works or QR works' OR works' OR works' OR worka' OR worka' OR workge OR works' OR worka' OR "Biomechanics' OR "Physical Exertion" OR "Torsion, Mechanical" OR "Postural Balance' OR "Walking" OR "Recovery of Function" OR "Relaxation" OR (static AND posture) OR (awkward AND posture) OR (dynamic AND posture) OR (static AND work) OR (dynamic AND load*) OR lift* OR carry* OR hold* OR pull* OR drag* OR push* OR (manual AND handling) OR force* OR biomechanics' OR walking* OR (postural AND balance) OR flexion* OR extension* OR turning OR sitting OR kneeling OR squatting OR twisting OR bending OR reaching OR standing OR sedentary OR (repetitive AND movement*) OR (monotonous AND work) OR relaxation OR (recovery AND of AND function) OR (physical AND demand*) OR (physically AND demand*)) OR ("Stress, Psychological"/exp OR "Stress, Psychological" OR "Social Support"/exp OR "Social Support" OR "Job Satisfaction" (exp OR "Social Justice/psychology" OR "Personnel Downsizing"/exp OR "Personnel Downsizing"/exp OR "Staff Development"/exp OR "Staff Development" OR "Organizational Culture"/exp OR "Social Discrimination"/exp OR "Bullying" OR "Prejudice"/exp OR "Interpersonal Relations"/OR (work AND demand*) OR (high AND demand*) OR (low AND control) OR (decision AND demand*) OR (low AND control) OR (decision AND lati

	over-load*) OR recovery OR coping OR (work AND ability) OR (social AND support) OR (support AND system*) OR (social AND network*) OR (emotional AND support) OR (interpersonal AND relation*) OR interaction* OR justice* OR injustice* OR (job AND satisfaction) OR (work AND satisfaction) OR boredom OR (skill AND discretion*) OR (staff AND development) OR discrimination OR harass* OR (work-place AND conflict*) OR (workplace AND violen*) OR (workplace AND violen*) OR bullying OR ageism OR homophobia OR racism OR sexism OR victimization* OR (silent AND workplace*) OR (role AND ambiguity) OR role-conflict* OR work-role* OR (working AND hour*) OR (working AND time) OR day-time OR night-time OR (shift AND work*) OR (work AND shift*) OR (temporary AND work) OR full-time OR part-time OR (flexible AND work*) OR (organizational AND change) OR (organizational AND change) OR (lean AND production) OR (job AND security) OR (job AND insecurity))) AND (((("inflammation" OR inflammation*) OR ("immune system" OR "immune system phenomena" OR "immunity" OR "immunology")) OR ("c-reactive protein" OR ("c-reactive" AND protein) OR c-reactive protein OR CRP) OR ("cytokines" OR cytokine*) OR ("lymphokines" OR lymphokine*) OR ("chemokines" OR chemokine*) OR ("monokines" OR monokine*) OR ("tumor necrosis factor-alpha" OR tumor necrosis factor* OR ("tumor" AND "necrosis" AND factor*) OR TNF*) OR ("interleukins" OR interleukin* OR IL)) AND ((longitudinal study) OR (prospective cohort study) OR (prospective studies) OR (follow-up studies) OR (observational stud*))
Japan Medical	(労働 OR 従業員 OR 社員 OR ワークサンプル OR 同僚 OR 仲間 OR 上司 OR 管理 OR 監督 OR マネージャー
Abstracts	ORマネジャー OR 課長 OR 部長 OR 主任 OR 上長 OR 役員 OR チーフ OR リーダー OR 上役 OR 雇い主 OR
Society	雇主 OR 雇用 OR ワークグループ OR 仕事 OR ワーク OR 作業 OR 就労 OR 勤務 OR ワーキング OR 働く OR
•	職場 OR オフィス OR 研究所 OR 診療所 OR 医院 OR 事業 OR 職業 OR 家業 OR 事務 OR 業務 OR 執務 OR
	営業 OR 所業 OR 実業 OR 産業 OR 就業 OR 企業 OR 会社 OR 商会 OR 法人)AND
	(機械的ストレス OR 持ちあげ OR 患者の移動 OR 患者の持ち上げ OR 荷重負荷 OR 体重負荷 OR 生物力学 OR
	労作 OR 機械的ねじれ OR 姿勢 OR バランス OR ウォーキング OR 歩行 OR 機能的回復 OR リラクセーション
	OR 静的姿勢 OR 窮屈な姿勢 OR 動的姿勢 OR 静的労働 OR 動的負荷 OR 持ちあげ OR 運搬 OR 抱え込み OR
	引き OR 引きずり OR 押し OR 手作業 OR 力 OR 生物力学 OR ウォーキング OR 歩行 OR 姿勢 OR バランス
	OR 屈曲 OR 伸長 OR 拡張 OR 回転 OR 座位 OR 座り OR 膝曲げ OR スクワット OR より合わせ OR 曲げ
	OR 伸ばし OR 立位 OR 座位 OR 反復運動 OR 単調動作 OR 単調な仕事 OR リラクセーション OR 機能的回復
	OR 身体的負荷 OR 身体的 OR 負荷) OR (心理的ストレス OR ソーシャル・サポート OR 仕事の満足度 OR 仕事
	のストレス耐性 OR 従業員のパフォーマンス評価 OR 従業員の抗議 OR (社会的正義 AND 心理学) OR 人員削減
	OR 従業員教育 OR 組織文化 OR いじめ OR 偏見 OR 社会的差別 OR 対人関係 OR (コミュニケーション AND
	心理学)) OR (心理社会的 OR 仕事のストレイン OR 仕事のストレス OR 仕事の要求度 OR 高い要求度 OR 低いコ
	ントロール OR コントロールの欠如 OR 仕事のコントロール OR 裁量の範囲 OR 仕事の影響 OR 要求度資源 OR
	努力報酬 OR 時間的切迫 OR 病気からの回復 OR 療養 OR 仕事の負担 OR 回復 OR コーピング OR 対処 OR

	職務能力 OR 社会的支援 OR ソーシャルサポート OR 支援システム OR サポートシステム OR 社会的ネットワー
	クOR ソーシャルネットワーク OR 情緒的支援 OR 情緒的サポート OR 対人関係 OR 人間関係 OR 対人交流 OR
	相互作田 OR 公正 OR 不公正 OR 聯發法見感 OR 退屋 OR 技能の幅 OR 聴昌研修 OR 美別 OR 嫌がらせ OR
	戦場のる膝 OK 戦場の泰力 OK いしめ OK 午野左別 OK 回性愛左別 OK 八悝左別 OK 性左別 OK 虐侍 OK 前
	かな職場 OR 役割曖昧さ OR 役割葛藤 OR 仕事での役割 OR 労働時間 OR 勤務時間 OR 日中 OR 夜間 OR シ
	フト業務 OR 交代勤務 OR 時間差勤務 OR 臨時業務 OR フルタイム OR パートタイム OR フレックス制度 OR
	組織改革 OR 組織再編 OR リーン生産 OR トヨタ生産方式 OR 安定雇用 OR 不安定雇用)AND
	(炎症 OR 免疫 OR C反応性 OR CRP OR サイトカイン OR リンホカイン OR ケモカイン OR モノカイン OR 腫瘍
	壊死性因子 OR TNE OR インターロイキン OR IL) AND
	(紛敗研究 OP 前向きったート研究 OP 前向き研究 OP 追随研究 OP フェローアップ研究 OP 細索研究)
,	
	4
	For poor review only http://bmienen.hmi.com/site/about/avidalines.yhtml
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xntml

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

~~~~ <b>r</b> ~~	Item No	Checklist item	On page #
ADMINISTRATIVE I	NFOR	RMATION	
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	P. 1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	N/A
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	P.4
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	P.1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	P. 10
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	N/A
Support:			
Sources	5a	Indicate sources of financial or other support for the review	N/A
Sponsor	5b	Provide name for the review funder and/or sponsor	P. 9
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	P. 10
INTRODUCTION			
INTRODUCTION Rationale	6	Describe the rationale for the review in the context of what is already known	P. 5-6
INTRODUCTION Rationale Objectives	6 7	Describe the rationale for the review in the context of what is already known Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	P. 5-6 P. 6
INTRODUCTION Rationale Objectives METHODS	6 7	Describe the rationale for the review in the context of what is already known Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	P. 5-6 P. 6
INTRODUCTION Rationale Objectives METHODS Eligibility criteria	6 7 8	Describe the rationale for the review in the context of what is already known Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	P. 5-6 P. 6 P. 6-7
INTRODUCTION Rationale Objectives METHODS Eligibility criteria Information sources	6 7 8 9	Describe the rationale for the review in the context of what is already known         Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)         Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review         Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	P. 5-6 P. 6 P. 6-7 P. 7

Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	P. 7-8
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	P. 7-8
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	P. 7-8
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	P. 7-8
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	P. 7-8
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	P. 8
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	P. 8-9
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as $I^2$ , Kendall's $\tau$ )	P. 8-9
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	P. 9
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	N/A
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	P. 9
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	N/A

* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

# **BMJ Open**

# **Psychosocial factors at work and inflammatory markers:** protocol for a systematic review and meta-analysis

Journal:	BMJ Open
Manuscript ID	bmjopen-2018-022612.R1
Article Type:	Protocol
Date Submitted by the Author:	06-Jun-2018
Complete List of Authors:	Eguchi, Hisashi; Kitasato University School of Medicine, Department of Public Health Watanabe, Kazuhiro; The University of Tokyo, Department of Mental Health, Graduate School of Medicine Kawakami, Norito; The University of Tokyo, Department of Mental Health Ando, Emiko; Osaka University, Department of Social and Environmental Health, Division of Environmental Medicine and Population Sciences, Graduate School of Medicine Arima, Hideaki; The University of Tokyo, Department of Mental Health, Graduate School of Medicine Asai, Yumi; The University of Tokyo, Department of Mental Health, Graduate School of Medicine Inoue, Akiomi; Kitasato University School of Medicine, Department of Public Health Inoue, Reiko; Hitachi Automotive Systems Ltd Iwanaga, Mai; Graduate School of Medicine, The university of Tokyo, Department of Psychiatric Nursing Imamura, Kotaro; The University of Tokyo, Department of Mental Health, Graduate School of Medicine Kobayashi, Yuka; Honda Motor Co., Ltd. Nishida, Norimitsu; Kyoto Industrial Health Association Otsuka, Yasumasa; Faculty of Human Sciences, University of Tsukuba Sakuraya, Asuka; The University of Tokyo, Department of Mental Health, Graduate School of Medicine Tsuno, Kanami; Wakayama Medical University - Kimiidera Campus, Department of Hygiene, School of Medicine Shimazu, Akihito; College of Liberal Arts and Sciences, Kitasato University, Tsutsumi, Akizumi; Kitasato University, Department of Public Health
<b>Primary Subject Heading</b> :	Occupational and environmental medicine
Secondary Subject Heading:	Immunology (including allergy)
Keywords:	Inflammation, Psychosocial factors at work, Cardiology < INTERNAL MEDICINE, Occupational health, Workplace, MENTAL HEALTH

1 2 3 4 5 6 7	SCHOLARONE [™] Manuscripts
8 9 10 11 12 13 14 15 16 17 18 19 20 21 20 21 22 23	
24 25 26 27 28 29 30 31 32 33 34 35 36 27	
37 38 39 40 41 42 43 44 45 46 47 48 49 50	
52 53 54	

1 Psychosocial factors at work and inflammatory markers: protocol for a 2 systematic review and meta-analysis

## Authors

Hisashi Eguchi^{1*}, Kazuhiro Watanabe^{2,3*}, Norito Kawakami², Emiko Ando⁴,
 Hideaki Arima², Yumi Asai², Akiomi Inoue¹, Reiko Inoue⁵, Mai Iwanaga⁶, Kotaro
 Imamura², Yuka Kobayashi⁷, Norimitsu Nishida⁸, Yasumasa Otsuka⁹, Asuka
 Sakuraya², Kanami Tsuno¹⁰, Akihito Shimazu¹¹, Akizumi Tsutsumi¹

- ¹Department of Public Health, Kitasato University School of Medicine,
   Sagamihara, Japan
- ²Department of Mental Health, Graduate School of Medicine, The University of
   Tokyo, Tokyo, Japan
- ¹⁴ ³The Japan Society for the Promotion of Science, Tokyo, Japan
- ¹⁵ ⁴Division of Environmental Medicine and Population Sciences, Department of
- Social and Environmental Medicine, Graduate School of Medicine, Osaka
   University, Osaka, Japan
- ¹⁸ ⁵Hitachi Automotive Systems, Ltd., Hitachinaka, Japan
- ⁶Department of Psychiatric Nursing, Graduate School of Medicine, The
   University of Tokyo, Tokyo, Japan
- ²¹ ⁷Honda Motor Co., Ltd., Tokyo, Japan
- 22 ⁸Kyoto Industrial Health Association, Kyoto, Japan
- ²³ ⁹Faculty of Human Sciences, University of Tsukuba, Tokyo, Japan
  - ¹⁰Department of Hygiene, School of Medicine, Wakayama Medical University,
- 25 Wakayama, Japan
  - ²⁶ ¹¹Center for Human and Sciences, College of Liberal Arts and Sciences,
  - 27 Kitasato University, Sagamihara, Japan
  - ²⁸ *HE and KW made equal contributions to this study.

# 30 Corresponding author

- 31 Akizumi Tsutsumi
- 32 Department of Public Health, Kitasato University School of Medicine, Japan
- 1-15-1 Kitasato, Minami-ku, Sagamihara-shi, Kanagawa 252-0374, Japan
- 34 E-mail address: akizumi@kitasato-u.ac.jp
- 35 Phone: +81-42-778-9352
- 36 Fax: +81-42-778-9257

1 2		
3 4		
5 6	37	Ward county 2.016 words
7 8	38	word count: 2,016 words
9 10		
11 12		
13 14		
15		
17		
19		
20		
22		
24 25		
26 27		
28 29		
30 31		
32 33		
34 35		
36 37		
38 39		
40 41		
42 43		
44 45		
46 47		
48 49		
50 51		
52 53		
54 55		
56 57		2
58 59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

## 39 Abstract

**INTRODUCTION:** Chronic inflammation may be a mediator for the development of cardiovascular disease (CVD), metabolic diseases, and psychotic and neurodegenerative disorders. Meta-analytic associations between work-related psychosocial factors and inflammatory markers have shown that work-related psychosocial factors could affect the flexibility and balance of the immune system. However, few systematic reviews or meta-analyses have investigated the association between work-related psychosocial factors and inflammatory markers. Based on prospective studies, the present investigation will conduct a comprehensive systematic review and meta-analysis of the association between work-related psychosocial factors and inflammatory markers. **METHODS AND ANALYSIS:** The systematic review and meta-analysis will include published studies identified from electronic databases (PubMed, EMBASE, PsycINFO, PsycARTICLES, Web of Science and Japan Medical Abstracts Society) according to recommendations of the Meta-analysis of Observational Studies in Epidemiology guideline. Inclusion criteria are studies that did the following: examined associations between work-related psychosocial factors and increased inflammatory markers; used longitudinal or prospective cohort designs; were conducted among workers; provided sufficient data for calculating odds ratios or relative risk with 95% confidence intervals; were published as original articles in English or Japanese; and were published up to the end of 2017. Study selection, data extraction, quality assessment, and statistical syntheses will be conducted by 14 investigators. Any inconsistencies or disagreements will be resolved through discussion. The quality of studies will be evaluated using the Risk of Bias Assessment Tool for Nonrandomized Studies. ETHICS AND DISSEMINATION: The investigation study will be based on 

published studies, so ethics approval is not required. The results of this study will
 be submitted for publication in a scientific peer-reviewed journal. The findings
 may be useful for assessing risk factors for increased inflammatory markers in
 the workplace and determining future approaches for preventing CVD, metabolic
 diseases, and psychotic and neurodegenerative disorders.
 TRIAL REGISTRATION NUMBER: PROSPERO CRD42018081553

72 (https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=81553).

75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 92 93	<ul> <li>This systematic review and meta-analysis will offer comprehensive understanding of the association between work-related psychosocial factor and inflammatory markers.</li> <li>The review will include a range of work-related psychosocial factors and focus on inflammatory markers.</li> <li>To ensure stronger evidence, the review will include only prospective studies.</li> <li>The findings of this review may be useful for assessing chronic inflammat as a risk factor for cardiovascular disease (CVD), metabolic diseases, and psychotic and neurodegenerative disorders in the workplace as well as for determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that material cardiovascular for the confounding factors that material cardiovascular for the confounding factors that material cardiovascular for the confounding factors for the confounding factors that material cardiovascular for the cardiovascular for the confounding factors that material cardiovascular for the cardiovascular for the confounding factors that material cardiovascular for the cardiovascular for the confounding factors that material cardiovascular for the cardiovascular</li></ul>
76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 92 93	<ul> <li>understanding of the association between work-related psychosocial factors and inflammatory markers.</li> <li>The review will include a range of work-related psychosocial factors and focus on inflammatory markers.</li> <li>To ensure stronger evidence, the review will include only prospective studies.</li> <li>The findings of this review may be useful for assessing chronic inflammat as a risk factor for cardiovascular disease (CVD), metabolic diseases, and psychotic and neurodegenerative disorders in the workplace as well as for determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that market as a risk factor state.</li> </ul>
77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 92 93	<ul> <li>and inflammatory markers.</li> <li>The review will include a range of work-related psychosocial factors and focus on inflammatory markers.</li> <li>To ensure stronger evidence, the review will include only prospective studies.</li> <li>The findings of this review may be useful for assessing chronic inflammat as a risk factor for cardiovascular disease (CVD), metabolic diseases, and psychotic and neurodegenerative disorders in the workplace as well as for determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that material cardiovascular for the statement of the stateme</li></ul>
78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 92 93	<ul> <li>The review will include a range of work-related psychosocial factors and focus on inflammatory markers.</li> <li>To ensure stronger evidence, the review will include only prospective studies.</li> <li>The findings of this review may be useful for assessing chronic inflammat as a risk factor for cardiovascular disease (CVD), metabolic diseases, and psychotic and neurodegenerative disorders in the workplace as well as for determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that matched the provide the set of the set of</li></ul>
79 80 81 82 83 84 85 86 87 88 89 90 91 92 93	<ul> <li>The review will include a range of work-related psychosocial factors and focus on inflammatory markers.</li> <li>To ensure stronger evidence, the review will include only prospective studies.</li> <li>The findings of this review may be useful for assessing chronic inflammat as a risk factor for cardiovascular disease (CVD), metabolic diseases, and psychotic and neurodegenerative disorders in the workplace as well as for determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that matched as a results.</li> </ul>
80 81 82 83 84 85 86 87 88 89 90 91 92 93	<ul> <li>focus on inflammatory markers.</li> <li>To ensure stronger evidence, the review will include only prospective studies.</li> <li>The findings of this review may be useful for assessing chronic inflammat as a risk factor for cardiovascular disease (CVD), metabolic diseases, and psychotic and neurodegenerative disorders in the workplace as well as for determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that matches and particular disease (CVD) and particular diseases.</li> </ul>
81 82 83 84 85 86 87 88 89 90 91 92 92 93	<ul> <li>To ensure stronger evidence, the review will include only prospective studies.</li> <li>The findings of this review may be useful for assessing chronic inflammat as a risk factor for cardiovascular disease (CVD), metabolic diseases, and psychotic and neurodegenerative disorders in the workplace as well as for determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that matches the provide the terminant of the second structure of the terminant of terminant of the terminant of terminant of the terminant of t</li></ul>
82 83 84 85 86 87 88 89 90 91 92 93	<ul> <li>To ensure stronger evidence, the review will include only prospective studies.</li> <li>The findings of this review may be useful for assessing chronic inflammat as a risk factor for cardiovascular disease (CVD), metabolic diseases, and psychotic and neurodegenerative disorders in the workplace as well as for determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that matches the provide the results.</li> </ul>
83 84 85 86 87 88 89 90 91 91 92 93	<ul> <li>studies.</li> <li>The findings of this review may be useful for assessing chronic inflammat as a risk factor for cardiovascular disease (CVD), metabolic diseases, and psychotic and neurodegenerative disorders in the workplace as well as for determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that m</li> </ul>
84 85 86 87 88 89 90 91 92 92 93	<ul> <li>The findings of this review may be useful for assessing chronic inflammat as a risk factor for cardiovascular disease (CVD), metabolic diseases, an psychotic and neurodegenerative disorders in the workplace as well as for determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that metabolic diseases and the second sec</li></ul>
<ul> <li>85</li> <li>86</li> <li>87</li> <li>88</li> <li>89</li> <li>90</li> <li>91</li> <li>92</li> <li>93</li> </ul>	<ul> <li>The findings of this review may be useful for assessing chronic inflammat as a risk factor for cardiovascular disease (CVD), metabolic diseases, an psychotic and neurodegenerative disorders in the workplace as well as for determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that m</li> </ul>
86 87 88 89 90 91 92 93	<ul> <li>as a risk factor for cardiovascular disease (CVD), metabolic diseases, an psychotic and neurodegenerative disorders in the workplace as well as for determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that metabolic diseases.</li> </ul>
87 88 89 90 91 92 93	<ul> <li>psychotic and neurodegenerative disorders in the workplace as well as for determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that metabolic diseases.</li> </ul>
88 89 90 91 92 93	<ul> <li>determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that manual distributions and the results.</li> </ul>
89 90 91 92 93	<ul> <li>psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that manual statements.</li> </ul>
90 91 92 93	<ul> <li>Depending on the results, limitations could be confounding factors that m</li> </ul>
91 92 93	<ul> <li>Depending on the results, limitations could be confounding factors that m</li> </ul>
92 93	
93	not have been adjusted for in the selected studies as well as low
	4

# 94 INTRODUCTION

Most adults spend around half of their waking hours at work, and so the workplace is an important setting to promote health and well-being. Increasing attention is being directed to work-related psychosocial factors, such as job strain,¹⁻⁵ effort-reward imbalance,⁶ organizational justice,⁷⁻⁹ and workplace social capital¹⁰; there is a major focus on work stress.² These factors may affect cardiovascular disease (CVD), metabolic diseases, and psychotic and neurodegenerative disorders through such mechanisms as prolonged overactivation and dysregulation of the autonomic nervous system and the hypothalamus-pituitary-adrenal cortex axis.11-13 

Chronic inflammation has been suggested as a potential mediator for the development of CVD, metabolic diseases, and psychotic and neurodegenerative disorders.¹⁴⁻¹⁸ Several studies have reported associations between adverse work-related psychosocial factors and increased levels of inflammatory markers. Inflammatory markers, including C-reactive protein (CRP),¹⁹⁻²⁴ interleukin-6 (IL-6),^{24 25} and tumor necrosis factor (TNF- $\alpha$ ), have been implicated in coordinating atherosclerosis.²⁶ Previous meta-analyses^{27 28} have identified the associations between psychosocial factors and inflammatory markers; however, the findings from those studies were not conclusive because of methodological heterogeneity (e.g., conceptualization or measurement of work-related psychosocial factors, sample compositions, and statistical approaches). 

Meta-analytic associations between work-related psychosocial factors and inflammatory markers indicate that such factors may affect the flexibility and balance of the immune system. Some meta-analyses have investigated inflammatory markers in relation to psychological stress²⁷⁻³⁰ and

unemployment³¹; however, few systematic reviews or meta-analyses have been conducted regarding the associations between work-related psychosocial factors and inflammatory markers. A systematic review of 56 studies by Nakata³² suggested that work-related psychosocial factors were related to disrupted immune response. However, that study did not statistically synthesize the associations. To our knowledge, only one meta-analysis of the association between effort-reward imbalance and inflammatory markers (k = 7, N = 9952) found a negative association with immunity (r = -0.09; confidence interval [CI], -0.14 to -0.05; P < 0.001).¹³ These systematic reviews and meta-analyses included cross-sectional studies. However, pooled associations between work-related psychosocial factors and inflammatory markers derived from 

1		
2		
3		
4 5	100	progrative studios may provide more reliable svidence
6	130	prospective studies may provide more reliable evidence.
7	131	Based on published prospective studies, the present investigation will
8	132	conduct a comprehensive systematic review and meta-analysis of the
9 10	133	associations between work-related psychosocial factors and inflammatory
11	134	markers. Inflammatory markers will include those that were previously
12	135	investigated in terms of associations with psychosocial factors at work, including
13 14	136	CRP, IL-6, and TNF- $\alpha$ . Our hypothesis is that adverse work-related psychosocial
15	137	factors would increase inflammatory markers. Moreover, we will identify the
16	138	work-related psychological factors that have the strongest associations with
17 18	139	specific inflammatory markers.
19	140	
20	141	METHODS AND ANALYSIS
21	141	Study design
23	142	This study protocol for a systematic review and mate analysis of
24	143	This study protocol for a systematic review and meta-analysis of
25	144	prospective studies follows the Preferred Reporting Items for Systematic
20 27	145	Reviews and Meta-Analysis Protocols guideline. ³³ Future findings will be
28	146	reported according to the Meta-analysis of Observational Studies in
29	147	Epidemiology (MOOSE) reporting guidelines. ³⁴ This study protocol was
30 31	148	registered with PROSPERO (CRD42018081553).
32	149	
33	150	Eligibility criteria
34 35	151	Participants, exposures, comparisons, and outcomes (PECO) of the
36	152	studies included in this systematic review and meta-analysis will be defined as
37	152	follows: (P) inclusion of all workers: (E) presence of adverse psychosocial
38	153	factors at work: (C) absonage of adverse psychosocial factors at work: and (C)
39 40	154	increase ad influence store marketer. To not a perticipante will all be appalence of
41	155	increased inflammatory markers. Target participants will all be employees of
42	156	participating companies. There will be no exclusion criteria related to
43 44	157	employment status, job type, or shift type. The study exposures (adverse
45	158	psychosocial factors at work) will include a range of task and organizational
46	159	characteristics and work conditions, ³⁵ such as job strain, ¹⁻⁵ low social support,
47 48	160	effort-reward imbalance, ⁶ organizational injustice, ⁷⁻⁹ and low workplace social
49	161	capital. ¹⁰ Long working hours and shift work will also be included as target
50	162	exposures. Inflammatory markers will include those investigated in terms of
51 52	163	association with psychosocial factors at work in previous studies, including CRP.
52 53	164	$II_{-6}$ and TNF- $\alpha$
54	104	Eligibility criteria for selection are the following studies that (1) were
55	105	
56 57		C
58		ΰ
59		

conducted to evaluate associations between psychosocial factors at work and inflammatory markers; (2) used longitudinal or prospective cohort designs; (3) were conducted among workers; (4) provided sufficient data for calculating coefficients of associations between psychosocial factors at work and inflammatory markers ( $\gamma$ ,  $\beta$ ), odds ratios (ORs), relative risks (RRs), or hazard ratios (HRs) with standard errors (SEs) or 95% CIs; (5) were published as original articles in English or Japanese; and (6) were published up to the end of 2017. 

### 175 Information sources, search strategy, and data management

A systematic search of published studies will be conducted using electronic databases: PubMed (MEDLINE), EMBASE, PsycINFO, PsycARTICLES, Web of Science, and the Japan Medical Abstracts Society. Search terms will include words related to the PECO of eligible published studies. The proposed search strategy appears in Appendix 1. All identified studies will be managed in a Microsoft Excel file (WA, US). Before the study selection process, duplicated citations in the Excel file will be excluded by KW. Decisions on all studies will be recorded.

#### 185 Study selection process

First, following the eligibility criteria, 14 investigators (HE, KW, EA, HA, YA, AI, RI, MI, KI, YK, NN, YO, ASa, and KT) will independently conduct screening of identified titles and abstracts in pairs. Second, we will obtain full texts of all eligible studies. In the full-text review phase, the studies will be examined using a standardized form (Appendix 2) to assess eligibility for inclusion in this review. The number of papers examined by each investigator will depend on the investigator's capacity. Any discrepancies in assessment will be recorded and the inter-rater reliability determined; such matters will be discussed among all the investigators until consensus is reached. We will directly contact the corresponding authors of eligible studies if the results of the publication are unclear and may be related to multiple interpretations or if the reported results did not show data relevant to our study analysis. The reasons for excluding studies will be recorded. A flow chart will be prepared showing the entire review process. 

#### 201 Data extraction

Data will be extracted independently from the included studies by 14 investigators (HE, KW, EA, HA, YA, AI, RI, MI, KI, YK, NN, YO, ASa, and KT) working in pairs using a standardized data extraction form. The data will be distributed according to the investigators' capacity. Any discrepancies or inconsistencies in the assessment will be recorded and the inter-rater reliability determined; such matters will be discussed among all the investigators until consensus is reached. The extracted data will include the following: year of publication; country where the study was conducted; number of participants at baseline and in the analysis; sampling framework; participants' demographic characteristics (i.e., mean age, sex proportions, and employment status); length of follow-up; follow-up rate; exposure and comparison variables (adverse psychosocial factors at work); outcome variables (inflammatory markers); number and proportion of participants with increased levels of inflammatory markers or mean scores and variances or standard deviations of markers; and sufficient data for calculating the coefficients ( $\beta$ ,  $\gamma$ ), ORs, RRs, or HRs with SEs or 95% CIs for the association between adverse psychosocial factors at work and inflammatory markers. If the included studies report multiple measures of association, we will attempt to select measures of association adjusted by demographic variables (e.g., age, sex, education, and marital status). If the studies report measures of association adjusted by lifestyle variables (e.g., smoking, physical activity, and sleep), we will as far as possible extract measures both with and without adjustment for lifestyle variables. To avoid over-adjustment, measures of association adjusted for other adverse psychosocial factors at work or inflammatory markers will not be adopted. Sex-stratified coefficients will be selected if they are the only reported results. Any missing data from the studies will be obtained by contacting the relevant research team.

#### 230 Assessment of study quality

Fourteen investigators (HE, KW, EA, HA, YA, AI, RI, MI, KI, YK, NN, YO, ASa, and KT) will independently assess in pairs the quality of each included study using the internationally recognized Risk of Bias Assessment Tool for Nonrandomized Studies (RoBANS).^{36 37} The RoBANS was developed to determine the risk of bias of non-randomized studies; it comprises six domains: selection of participants; confounding variables; measurement of exposure; blinding of outcomes; incomplete outcome data; and selective outcome reporting.

The risk of bias for each domain is classified as low, high, or unclear risk. The number of papers assessed by each investigator will depend on their capacity. Any discrepancies in quality assessment among the investigators will be recorded and the inter-rater reliability determined; such matters will be discussed among all the investigators until consensus is reached.

## 244 Data synthesis and statistical methods

The included studies will be statistically synthesized in a meta-analysis to estimate pooled coefficients and 95% CIs, stratified by types of measures of association ( $\beta$ ,  $\gamma$ , OR, RR, and HR). If the included studies report ORs, RRs, or HRs, we will calculate log-transformed ORs, RRs, or HRs and determine SEs based on 95% CIs. These parameters will be used in the meta-analysis and for examining publication bias by means of a funnel plot and Egger's test with statistical software, R version 3.4.1.38 39 We will employ a random-effects model⁴⁰ to summarize the results using R version 3.4.1 with the "meta" and "metafor" packages.41 

For the main analysis, we will synthesize all types of psychosocial factors at work in the random-effects model. The results will be presented in a narrative format if a meta-analysis is not appropriate or possible, e.g., if only two or fewer studies are eligible and included in the study. Heterogeneity will be assessed using the chi-square test with Cochran's *Q* statistic, which is calculated by  $l^2$ values,⁴² assuming that  $l^2$  values of 25%, 50%, and 75% indicate low, medium, and high heterogeneity, respectively.

Subgroup and sensitivity analyses will be conducted to compare the results across subgroups or under specific conditions when sufficient heterogeneity is detected. Major possible grouping characteristics will include types of exposure and outcome, participants' demographic characteristics (e.g., sex, age, employment status, occupational groups), and study guality. Any subgroup differences will be reported, and our findings will be explained by considering these differences. Results with and without adjustment for lifestyle variables will be compared in another sensitivity analysis. If trends are observed between pooled associations and any grouping characteristics, meta-regression will be conducted using the "metareg" function of R. A sensitivity analysis may be conducted for included studies where the RoBANS is classified as low risk. All extracted data and analyzed results will be deposited by the corresponding author and made available for external reviewers and readers upon request. 

2		
3		
5	274	
6	274	Patient and public involvement statement
/	276	This study will not involve any natients or study participants: this study
9	210	netoool is for a systematic review and meto analysis
10	211	protocor is for a systematic review and meta-analysis.
11 12	278	
12	279	Ethics and dissemination
14	280	This study does not require ethical approval because the systematic review and
15	281	meta-analysis will be based on previously published studies. The results will be
16 17	282	submitted for publication in a scientific peer-reviewed journal, according to the
18	283	MOOSE guideline. ³⁴
19	284	
20	285	Funding
22	286	This work is supported by the Work-related Diseases Clinical Research Grant
23	287	2016 (160701-01) from the Ministry of Health   abour and Welfare Japan The
24 25	201	funder has no role in study design, data extraction and analysis, decision to
25	200	nullich, or proparation of the final manuscript
27	289	
28	290	
29 30	291	Competing Interests
31	292	The authors declare that they have no competing interests.
32	293	
33 34	294	Strengths and limitations
35	295	This systematic review and meta-analysis will be based on prospective studies
36	296	and show the strongest evidence for the associations between psychosocial
37 38	297	factors at work and inflammatory markers. The findings will highlight potential
39	298	mediators and underlying mechanisms for the development of CVD owing to
40	299	adverse psychosocial factors.
41 42	300	There are several likely limitations in this study, including confounding
43	301	bias and low generalizability. If selected studies do not report
44	302	demographic-adjusted associations, the findings will be distorted by the
45 46	303	unobserved characteristics among the population. In addition, the findings will
47	000	not be generalizable to populations not included in the colocted studios
48	304	not be generalizable to populations not included in the selected studies.
49 50	305	
51	306	Authors' contributions
52	307	HE, KW, NK, EA, HA, YA, AI, RI, MI, KI, YK, NN, YO, ASa, KT, ASh, and AT
53 54	308	made substantial contributions to the conception and design of the study, writing
54 55	309	the protocol and revising it critically for important intellectual content, and
56		
57		10
58 59		

310	app	proving the final version to be published. All authors will be involved in the
311	ent	ire study process (i.e., data extraction, assessment, and synthesis).
312		
313	Ac	knowledgements
314	We	e thank Audrey Holmes, MA, from Edanz Group (www.edanzediting.com/ac)
315	for	editing a draft of this manuscript.
316		
317	Rei	ferences
318	1.	Kivimaki M, Nyberg ST, Batty GD, et al. Job strain as a risk factor for
319		coronary heart disease: a collaborative meta-analysis of individual
320		participant data. <i>Lancet</i> 2012;380:1491–7.
321		doi:10.1016/s0140-6736(12)60994-5
322	2.	Kivimaki M, Kawachi I. Work stress as a risk factor for cardiovascular
323		disease. Curr Cardiol Rep 2015;17:630. doi: 10.1007/s11886-015-0630-8
324	3.	Fishta A, Backe EM. Psychosocial stress at work and cardiovascular
325		diseases: an overview of systematic reviews. Int Arch Occup Environ Health
326		2015;88:997–1014. doi:10.1007/s00420-015-1019-0
327	4.	Theorell T, Karasek RA. Current issues relating to psychosocial job strain
328		and cardiovascular disease research. <i>J Occup Health Psychol</i> 1996;1:9–26.
329	5.	Belkic KL, Landsbergis PA, Schnall PL, et al. Is job strain a major source of
330		cardiovascular disease risk? Scand J Work Environ Health 2004;30:85–128.
331	6.	Siegrist J. Adverse health effects of high-effort/low-reward conditions. J
332		Occup Health Psychol 1996;1:27–41.
333	7.	De Vogli R, Ferrie JE, Chandola T, et al. Unfairness and health: evidence
334		from the Whitehall II Study. <i>J Epidemiol Community Health</i> 2007;61:513–8.
335		doi:10.1136/jech.2006.052563
336	8.	Elovainio M, Leino-Arjas P, Vahtera J, et al. Justice at work and
337		cardiovascular mortality: a prospective cohort study. J Psychosom Res
338		2006;61:271–4. doi:10.1016/j.jpsychores.2006.02.018
339	9.	Kivimaki M, Ferrie JE, Brunner E, et al. Justice at work and reduced risk of
340		coronary heart disease among employees: the Whitehall II Study. Arch
341		Intern Med 2005;165:2245–51. doi:10.1001/archinte.165.19.2245
342	10.	Oksanen T, Kawachi I, Jokela M, et al. Workplace social capital and risk of
343		chronic and severe hypertension: a cohort study. J Hypertens
344		2012;30:1129–36. doi:10.1097/HJH.0b013e32835377ed
345	11.	Kivimaki M, Virtanen M, Elovainio M, et al. Work stress in the etiology of
		11

3			
4	0.40		coronary boart discourse a moto analysis. Second 114/arts Environ Health
6	346		coronary heart disease—a meta-analysis. Scand J work Environ Health
7	347		2006;32:431–42.
8	348	12.	Barth J, Schneider S, von Kanel R. Lack of social support in the etiology and
9 10	349		the prognosis of coronary heart disease: a systematic review and
11	350		meta-analysis. Psychosom Med 2010;72:229–38.
12	351		doi:10.1097/PSY.0b013e3181d01611
13 14	352	13.	Eddy P, Heckenberg R, Wertheim EH, et al. A systematic review and
15	353		meta-analysis of the effort-reward imbalance model of workplace stress with
16	354		indicators of immune function. <i>J Psychosom Res</i> 2016;91:1–8.
17	355		doi:10.1016/i.jpsychores.2016.10.003
19	356	14	Lopez-Candales A Hernandez Burgos PM Hernandez-Suarez DE et al
20	357		Linking chronic inflammation with cardiovascular disease: From normal
21	250		aging to the metabolic syndrome. I Not Sei 2017:2:0241
23	500	15	Signification of the development of chronic discourse. Int.
24	359	15.	Siegnst J, Li J. Work stress and the development of chronic diseases. <i>Int J</i>
25 26	360		Environ Res Public Health 2018;15(3) doi: 10.3390/ijerph15030536
27	361	16.	Raiston JC, Lyons CL, Kennedy EB, et al. Fatty acids and NLRP3
28	362		inflammasome-mediated inflammation in metabolic tissues. Annu Rev Nutr
29	363		2017;37:77–102. doi: 10.1146/annurev-nutr-071816-064836
31	364	17.	Singh B, Chaudhuri TK. Role of C-reactive protein in schizophrenia: an
32	365		overview. Psychiatry Res 2014;216:277-85. doi:
33	366		10.1016/j.psychres.2014.02.004
34 35	367	18.	Dopkins N, Nagarkatti PS, Nagarkatti M. The role of gut microbiome and
36	368		associated metabolome in the regulation of neuroinflammation in multiple
37	369		sclerosis and its implications in attenuating chronic inflammation in other
38 39	370		inflammatory and autoimmune disorders. <i>Immunology</i> 2018 (in press) doi:
40	371		10 1111/imm 12903
41	279	10	Equebi H. Shimazu A. Kawakami N. et al. Source specific workplace social
42 43	072	19.	cuppert and high appointivity C reactive protein levels among lengages
44	373		support and high-sensitivity C-reactive protein levels among Japanese
45	374		workers: A 1-year prospective conort study. Am J Ind Med 2016;59:676–84.
46 47	375		doi:10.1002/ajim.22600
48	376	20.	Tsai SS, Lai CH, Shih TS, et al. High job strain is associated with
49	377		inflammatory markers of disease in young long-haul bus drivers. J Occup
50 51	378		Health Psychol 2014;19:336–47. doi:10.1037/a0036600
52	379	21.	Emeny R, Lacruz ME, Baumert J, et al. Job strain associated CRP is
53	380		mediated by leisure time physical activity: results from the MONICA/KORA
54 55	381		study. Brain Behav Immun 2012;26:1077–84. doi:10.1016/j.bbi.2012.07.004
56			
57			12
58 50			
60			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

382	22.	Xu W, Chen B, Guo L, et al. High-sensitivity CRP: possible link between job
383		stress and atherosclerosis. Am J Ind Med 2015;58:773–9.
384		doi:10.1002/ajim.22470
385	23.	Almadi T, Cathers I, Hamdan Mansour AM, et al. The association between
386		work stress and inflammatory biomarkers in Jordanian male workers.
387		Psychophysiology 2012;49:172–7. doi:10.1111/j.1469-8986.2011.01296.x
388	24.	Elovainio M, Ferrie JE, Singh-Manoux A, et al. Organisational justice and
389		markers of inflammation: the Whitehall II study. Occup Environ Med
390		2010;67:78–83. doi:10.1136/oem.2008.044917
391	25.	Nakata A, Irie M, Takahashi M. Source-specific social support and circulating
392		inflammatory markers among white-collar employees. Ann Behav Med
393		2014;47:335–46. doi:10.1007/s12160-013-9555-x
394	26.	Ridker PM, Luscher TF. Anti-inflammatory therapies for cardiovascular
395		disease. Eur Heart J 2014;35:1782–91. doi:10.1093/eurheartj/ehu203
396	27.	Herbert TB, Cohen S. Stress and immunity in humans: a meta-analytic
397		review. <i>Psychosom Med</i> 1993;55:364–79.
398	28.	Segerstrom SC, Miller GE. Psychological stress and the human immune
399		system: a meta-analytic study of 30 years of inquiry. Psychol Bull
400		2004;130:601–30. doi:10.1037/0033-2909.130.4.601
401	29.	Steptoe A, Hamer M, Chida Y. The effects of acute psychological stress on
402		circulating inflammatory factors in humans: A review and meta-analysis.
403		Brain Behav Immun 2007;21:901–12. doi:10.1016/j.bbi.2007.03.011
404	30.	Marsland AL, Walsh C, Lockwood K, et al. The effects of acute psychological
405		stress on circulating and stimulated inflammatory markers: A systematic
406		review and meta-analysis. Brain Behav Immun 2017;64:208–19.
407		doi:10.1016/j.bbi.2017.01.011
408	31.	Hughes A, Kumari M, McMunn A, et al. Unemployment and inflammatory
409		markers in England, Wales and Scotland, 1998–2012: Meta-analysis of
410		results from 12 studies. Brain Behav Immun 2017;64:91–102.
411		doi:10.1016/j.bbi.2017.03.012
412	32.	Nakata A. Psychosocial job stress and immunity: A systematic review. In:
413		Yan Q, ed. Psychoneuroimmunology: Methods and Protocols. Totowa, NJ:
414		Humana Press 2012:39–75.
415	33.	Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for
416		systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.
417		Systematic Reviews 2015;4:1. doi:10.1186/2046-4053-4-1
		13
		**

60

1		
2		
3		
4 5	418	34. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational
0 7	419	studies in epidemiology: a proposal for reporting. Meta-analysis Of
8	420	Observational Studies in Epidemiology (MOOSE) group, JAMA
9	421	2000:283:2008–12
10	121	35 Semmer NK Job stress interventions and the organization of work Scand J
12	423	Work, Environ Health 2006;32(6):515–27.
13	424	36. Kim SY. Park JE. Lee YJ. et al. Testing a tool for assessing the risk of bias
14	425	for nonrandomized studies showed moderate reliability and promising
16	426	validity <i>J Clin Epidemiol</i> 2013:66:408-14, doi: 10.1016/i.iclinepi.2012.09.016
17 18	427	[published Online First: 2013/01/23]
19	428	37 Wells G. Shea B. O'Connell D. The Newcastle-Ottawa Scale (NOS) for
20	429	assessing the quality of nonrandomized studies in meta-analyses
21	120	Secondary The Newcastle-Ottawa Scale (NOS) for assessing the quality of
23	401	percendemined studies in meta analyzes, 2014, Available from:
24	431	
25	432	http://www.onri.ca/programs/clinical_epidemiology/oxford.asp
27	433	38. Watanabe K, Imamura K, Kawakami N. Working hours and the onset of
28	434	depressive disorder: a systematic review and meta-analysis. Occup Environ
29	435	Med 2016;73:877–84. doi:10.1136/oemed-2016-103845
31	436	39. Sakuraya A, Watanabe K, Kawakami N, et al. Work-related psychosocial
32	437	factors and onset of metabolic syndrome among workers: a systematic
33 34	438	review and meta-analysis protocol. BMJ Open 2017;7:e016716.
35	439	doi:10.1136/bmjopen-2017-016716
36	440	40. Hunter JE, Schmidt FL. Fixed effects vs. random effects meta-analysis
3/	441	models: Implications for cumulative research knowledge. Int J Sel Assess
39	442	2000;8:275–92. doi:10.1111/1468-2389.00156
40	443	41. Team RC. R: A language and environment for statistical computing. Vienna,
41	444	Austria: R Foundation for Statistical Computing; 2014.
43	445	42. Higgins J. Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat
44	446	Med 2002:21:1539–58
45 46	110	
47		
48		
49 50		
50		
52		
53		
54 55		
56		
57		14

# Appendix 1. Search terms used for the electronic databases

Database	Search terms
PubMed	(employe*[tw] OR manag*[tw] OR colleague*[tw] OR worksit*[tw] OR "work"[tw] OR works*[tw] OR work'*[tw] OR
	worka*[tw] OR worke*[tw] OR workg*[tw] OR worki*[tw] OR workl*[tw] OR workp*[tw] OR occupant*[tw] OR company*[tw]
	OR offic*[tw] OR busines*[tw] OR workplace[mh]) AND
	(("Stress, Mechanical"[Mesh] OR "Lifting"[Mesh] OR "Moving and Lifting Patients"[Mesh] OR "Weight-Bearing"[Mesh] OR
	"Biomechanics" OR "Physical Exertion" [Mesh] OR "Torsion, Mechanical" [Mesh] OR "Postural Balance" [Mesh] OR
	"Walking"[Mesh] OR "Recovery of Function"[Mesh] OR "Relaxation"[Mesh] OR (static[Title/Abstract] AND posture) OR
	(awkward[Title/Abstract] AND posture) OR (dynamic[Title/Abstract] AND posture) OR static work[Title/Abstract] OR dynamic
	load*[Intle/Abstract] OR Intl*[Intle/Abstract] OR carry*[Intle/Abstract] OR hold*[Intle/Abstract] OR pull*[Intle/Abstract] OR
	drag*[Intle/Abstract] OR push*[Intle/Abstract] OR manual handling[Intle/Abstract] OR force*[Intle/Abstract] OR
	otomechanic [Inte/Adstract] OK walking [Inte/Adstract] OK postural balance [Inte/Adstract] OK inexion [Inte/Adstract] OR extension*[Title/Abstract] OP turning[Title/Abstract] OP sitting[Title/Abstract] OP kneeling[Title/Abstract] OP
	squatting[Title/Abstract] OR twisting[Title/Abstract] OR hending[Title/Abstract] OR reaching[Title/Abstract] OR
	squatting[Title/Abstract] OR twisting[Title/Abstract] OR cenetitive movement*[Title/Abstract] OR monotonous
	work[Title/Abstract] OR relaxation[Title/Abstract] OR recovery of function[Title/Abstract] OR physical demand*[Title/Abstract]
	OR physically demand*[Title/Abstract]) OR ("Stress, Psychological"[Mair] OR "Social Support"[Mair] OR "Job
	Satisfaction"[Mesh] OR "Work Schedule Tolerance"[Mesh] OR "Employee Performance Appraisal"[Mesh] OR "Employee
	Grievances"[Mesh] OR "Social Justice/psychology"[Mesh] OR "Personnel Downsizing"[Mesh] OR "Staff Development"[Mesh]
	OR "Organizational Culture" [Mesh] OR "Bullying" [Mesh] OR "Prejudice" [Mesh] OR "Social Discrimination" [Mesh] OR
	"Interpersonal Relations"[Mesh] OR "Communication/psychology"[Mesh]) OR (psychosocial[Title/Abstract] OR job
	strain[Title/Abstract] OR work strain[Title/Abstract] OR work demand*[Title/Abstract] OR job demand*[Title/Abstract] OR high
	demand*[Title/Abstract] OR low control[Title/Abstract] OR lack of control[Title/Abstract] OR work control[Title/Abstract] OR job
	control[Title/Abstract] OR decision latitude[Title/Abstract] OR work influence*[Title/Abstract] OR demand
	resource*[Title/Abstract] OR effort reward*[Title/Abstract] OR time pressure*[Title/Abstract] OR recuperation*[Title/Abstract]
	OR work overload*[Title/Abstract] OR work over-load*[Title/Abstract] OR recovery[Title/Abstract] OR coping[Title/Abstract]
	OR work ability [litle/Abstract] OR social support [litle/Abstract] OR support system* [litle/Abstract] OR social
	network*[Inte/Abstract] OR emotional support[Inte/Abstract] OR interpersonal relation*[Inte/Abstract] OR
	interaction [*] [Inte/Abstract] OR social capital [Inte/Abstract] OR justice [*] [Inte/Abstract] OR injustice [*] [Inte/Abstract] OR job satisfaction[Title/Abstract] OR work satisfaction[Title/Abstract] OR howdow[Title/Abstract] OR situation*[Title/Abstract]
	Saustacuoni [ nue/Abstract] OK work saustacuoni [ nue/Abstract] OK boredoni [ nue/Abstract] OK skill discretion* [ nue/Abstract] OR staff davalonment[Title/Abstract] OR discrimination[Title/Abstract] OR harass*[Title/Abstract] OR work place
	OK stan development mic/Austracij OK dischnination mic/Austracij OK narass [mic/Austracij OK work-place

	conflict*[Title/Abstract] OR workplace violen*[Title/Abstract] OR work-place violen*[Title/Abstract] OR bullying[Title/Ab OR ageism[Title/Abstract] OR homophobia[Title/Abstract] OR racism[Title/Abstract] OR sexism[Title/Abstract] OR victimization*[Title/Abstract] OR silent workplace*[Title/Abstract] OR role ambiguity[Title/Abstract] OR role- conflict*[Title/Abstract] OR work-role*[Title/Abstract] OR working hour*[Title/Abstract] OR working time[Title/Abstract] day-time[Title/Abstract] OR night-time[Title/Abstract] OR shift work*[Title/Abstract] OR work shift*[Title/Abstract] OR
	organizational change[Title/Abstract] OR organisational change[Title/Abstract] OR lean production[Title/Abstract] OR job
	security[Ittle/Abstract] OR job insecurity[Ittle/Abstract])) AND (("inflammation"[MeSH Terms] OR inflammation*[All Fields]) OR ("immune system"[MeSH Terms] OR "immune system phenomena"[MeSH Terms] OR "immunity"[All Fields] OR "immunology"[All Fields])) OR ("c-reactive protein"[MeSH Ter OR ("a reactive"[All Fields] AND protein[All Fields]) OR a reactive protein[All Fields]) OR ("C-reactive protein"[MeSH Terms]
	("cytokines"[MeSH Terms] OR cytokine*[All Fields]) OR ("lymphokines"[MeSH Terms] OR lymphokine*[All Fields]) OR ("chemokines"[MeSH Terms] OR chemokine*[All Fields]) OR ("monokines"[MeSH Terms] OR monokine*[All Fields]) OR ("monokines"[MeSH Terms] OR monokines"[MeSH Terms] OR monokine
	("tumor necrosis factor-alpha"[MeSH Terms] OR tumor necrosis factor*[All Fields] OR ("tumor"[All Fields] AND "necrosis Fields] AND factor*[All Fields]) OR TNF*[All Fields]) OR ("interleukins"[MeSH Terms] OR interleukin*[All Fields] OR I Fields])) AND
	((longitudinal stud*) OR (prospective cohort stud*) OR (prospective stud*) OR (follow-up stud*) OR (observational stud*) (case-control stud*) OR (cohort stud*) OR (epidemiologic stud*) OR (cohort analy*) OR (observ* stud*) OR (retrospective
EMBASE,	(employe* OR manag* OR colleague* OR worksit* OR "work" OR works* OR work* OR worka* OR worke* OR workg*
PsycINFO/	worki* OR workl* OR workp* OR occupant* OR company* OR offic* OR busines* OR workplace) AND
PsycARTICLES	(("Stress, Mechanical" OR "Lifting" OR "Moving and Lifting Patients" OR "Weight-Bearing" OR "Biomechanics" OR "Phy
, Web of Science	(static AND posture) OR (awkward AND posture) OR (dynamic AND posture) OR (static AND work) OR (dynamic AND lo
	Walking* OR (postural AND balance) OR flexion* OR extension* OR turning OR sitting OR kneeling OR squatting OR twi OR bending OR reaching OR standing OR sedentary OR (repetitive AND movement*) OR (monotonous AND work) OR malanetics OR (reservery AND of AND function) OB (relevation (AND downend*)) OB ("Stray
	Psychological"/exp OR "Stress, Psychological" OR "Social Support"/exp OR "Social Support" OR "Job Satisfaction"/exp O Satisfaction" OR "Work Schedule Tolerance"/exp OR "Work Schedule Tolerance" OR "Employee Performance Appraisal"/e
	OR "Personnel Downsizing"/exp OR "Personnel Downsizing" OR "Staff Development"/exp OR "Staff Development" OR "Organizational Culture"/exp OR "Organizational Culture" OR "Bullying"/exp OR "Bullying" OR "Prejudice"/exp OR
	"Prejudice"/exp OR "Prejudice" OR "Social Discrimination"/exp OR "Social Discrimination" OR "Interpersonal Relations"/ "Interpersonal Relations" OR "Communication/psychology") OR (psychosocial OR (job AND strain) OR (work AND strain

	OR (work AND control) OR (job AND control) OR (decision AND latitude) OR (work AND influence*) OR (demand AND
	resource*) OR (effort AND reward*) OR (time AND pressure*) OR recuperation* OR (work AND overload*) OR (work AND
	over-load*) OR recovery OR coping OR (work AND ability) OR (social AND support) OR (support AND system*) OR (social
	AND network*) OR (emotional AND support) OR (interpersonal AND relation*) OR interaction* OR (social AND capital) OR
	justice* OR injustice* OR (job AND satisfaction) OR (work AND satisfaction) OR boredom OR (skill AND discretion*) OR (staff
	AND development) OR discrimination OR harass* OR (work-place AND conflict*) OR (workplace AND violen*) OR (workplace
	AND violen*) OR bullying OR ageism OR homophobia OR racism OR sexism OR victimization* OR (silent AND workplace*)
	OR (role AND ambiguity) OR role-conflict* OR work-role* OR (working AND hour*) OR (working AND time) OR day-time OR
	night-time OR (shift AND work*) OR (work AND shift*) OR (temporary AND work) OR full-time OR part-time OR (flexible
	AND work*) OR (organizational AND change) OR (organizational AND change) OR (lean AND production) OR (job AND
	security) OR (job AND insecurity))) AND
	((("inflammation" OR inflammation*) OR ("immune system" OR "immune system phenomena" OR "immunity" OR
	"immunology")) OR ("c-reactive protein" OR ("c-reactive" AND protein) OR c-reactive protein OR CRP) OR ("cytokines" OR
	cytokine*) OR ("lymphokines" OR lymphokine*) OR ("chemokines" OR chemokine*) OR ("monokines" OR monokine*) OR
	("tumor necrosis factor-alpha" OR tumor necrosis factor* OR ("tumor" AND "necrosis" AND factor*) OR TNF*) OR
	("interleukins" OR interleukin* OR IL)) AND
	((longitudinal stud*) OR (prospective cohort stud*) OR (prospective stud*) OR (follow-up stud*) OR (observational stud*) OR
	(case-control stud*) OR (cohort stud*) OR (epidemiologic stud*) OR (cohort analy*) OR (observ* stud*) OR (retrospective stud*)
Japan Medical	(労働 OR 従業員 OR 社員 OR ワークサンプル OR 同僚 OR 仲間 OR 上司 OR 管理 OR 監督 OR マネージャー
Abstracts	ORマネジャー OR 課長 OR 部長 OR 主任 OR 上長 OR 役員 OR チーフ OR リーダー OR 上役 OR 雇い主 OR
Society	雇主 OR 雇用 OR ワークグループ OR 仕事 OR ワーク OR 作業 OR 就労 OR 勤務 OR ワーキング OR 働く OR
·	職場 OR オフィス OR 研究所 OR 診療所 OR 医院 OR 事業 OR 職業 OR 家業 OR 事務 OR 業務 OR 執務 OR
	営業 OR 所業 OR 実業 OR 産業 OR 就業 OR 企業 OR 会社 OR 商会 OR 法人)AND
	(機械的ストレス OR 持ちあげ OR 患者の移動 OR 患者の持ち上げ OR 荷重負荷 OR 体重負荷 OR 生物力学 OR
	労作 OR 機械的ねじれ OR 姿勢 OR バランス OR ウォーキング OR 歩行 OR 機能的回復 OR リラクセーション
	OR 静的姿勢 OR 窮屈か姿勢 OR 動的姿勢 OR 静的労働 OR 動的負荷 OR 持ちあげ OR 運搬 OR 抱え込み OR
	しき OR 引きずり OR 押し OR 毛作業 OR 力 OR 生物力学 OR ウォーキング OR 歩行 OR 次勢 OR バランス
	OP $\square$
	On the on $\Delta U$
	OR 身体的負荷 OR 身体的 OR 負荷) OR (心理的ストレス OR ソーンヤル・サホート OR 仕事の満足度 OR 仕事
	のストレス耐性 OR 従業員のバフォーマンス評価 OR 従業員の抗議 OR (社会的止義 AND 心埋学) OR 人員削減
	OR 従業員教育 OR 組織文化 OR いじめ OR 偏見 OR 社会的差別 OR 対人関係 OR (コミュニケーション AND
	心理学)) OR (心理社会的 OR 仕事のストレイン OR 仕事のストレス OR 仕事の要求度 OR 高い要求度 OR 低いコ

 ントロール OR コントロールの欠如 OR 仕事のコントロール OR 裁量の範囲 OR 仕事の影響 OR 要求度資源 OR 努力報酬 OR 時間的切迫 OR 病気からの回復 OR 療養 OR 仕事の負担 OR 回復 OR コーピング OR 対処 OR 職務能力 OR 社会的支援 OR ソーシャルサポート OR 支援システム OR サポートシステム OR 社会的ネットワー クOR ソーシャルネットワーク OR ソーシャルキャピタル OR 情緒的支援 OR 情緒的サポート OR 対人関係 OR 人間関係 OR 対人交流 OR 相互作用 OR 公正 OR 不公正 OR 職務満足感 OR 退屈 OR 技能の幅 OR 職員研修 OR 差別 OR 嫌がらせ OR 職場の葛藤 OR 職場の暴力 OR いじめ OR 年齢差別 OR 同性愛差別 OR 人種差別 OR 性差別 OR 慮待 OR 静かな職場 OR 役割曖昧さ OR 役割葛藤 OR 仕事での役割 OR 労働時間 OR 勤務時間 OR 日中 OR 夜間 OR シフト業務 OR 交代勤務 OR 時間差勤務 OR 臨時業務 OR フルタイム OR パートタイム OR フレックス制度 OR 組織改革 OR 組織再編 OR リーン生産 OR トヨタ生産方式 OR 安定雇用 OR 不安定雇 用)AND (炎症 OR 免疫 OR C反応性 OR CRP OR サイトカイン OR リンホカイン OR ケモカイン OR モノカイン OR 腫瘍 壊死性因子 OR TNF ORインターロイキン OR L)AND (縦断研究 OR 前向きコホート研究 OR 前向き研究 OR 追跡研究 OR フォローアップ研究 OR 観察研究 OR 症例 対照研究 OR 後向き研究)

eview only

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

# Appendix 2. Standardized form to assess eligibility for inclusion

Effect of perturbative program and second perturbative program and second perturbative perturbat	1         Infect of transfording on properting         Special TLL Rate L. Journal of Machine Table 2014         Propue: To detache the sociation bowers transfording and properting department properind department propering department pr	Ellios de leading un generation de le de la desidad de la de	ID Database No	o Title	Author name	Source	Abstract	URL reviewer	1 reviewer 2	Result_ screening 1	Result_ screening 2	Resul
per revier	peer review only	Deer review only	1 Embase	Effect of breastfeeding on postpartum 1 depressive symptoms among adolescent and young adult mothers	Sipsma H.L., Ruiz E., Jones K., Magriples U. Kershaw T.,	Journal of Maternal-Fetal and Neonath Medicine (2018) 31:11 (1442-1447). Date of Publication: 3 Jun 2018	Purpose: To describe the association between breastfeeding and postpartum depressive symptoms among a sample of adolescent and young adult mothers and to determine whether breastfeeding difficulty moderates this association. Materials and methods: Data were derived from a prospective cohord pregnant adolescent and young adult formales (ages 14-21) as they transitioned to parenthood. This analysis uses data collected during pregnancy and at 6 months postpartum among mothers (n= 137) who initiated breastfeeding Multivariable linear regression was used to adjust for prental depressive symptoms and other potential confounders. Results: Postpartum depressive symptoms were not significantly associated with breastfeeding duration or breastfeeding at 6 months, Early breastfeeding difficulty moderated the association between depressive symptoms and breastfleeding at 6 months. Such breastfeeding difficulty and breastfeeding difficulty and breastfeeding at 6 months. Such breastfeeding difficulties had the low reported much early breastfeeding difficulty had the highest depressive scores at 6 months. Conclusions: Minimizing challenges with breastfeeding and persuntant breastfeeding and persuntant behavior approve postpartum mental health among adolescent and young adult mothers. Health care providers should bely young pregnant women manage expectations about breastfeeding and ensure that they are linked to appropriate professional breastfeeding support during the early postpartum period.	KW	HE	0	×	,
						-/	0000	<u>-</u>		<u> </u>		
						For peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml					

# PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

ADMINISTRATIVE I	NFOR	MATION	
Title:			
Identification	la	Identify the report as a protocol of a systematic review	P. 1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	N/A
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	P.3
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	P.1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	P. 10
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	N/A
Support:			
Sources	5a	Indicate sources of financial or other support for the review	N/A
Sponsor	5b	Provide name for the review funder and/or sponsor	P. 10
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	P. 10
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	P. 5-6
	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	P. 6
Objectives		comparators, and outcomes (1100)	
Objectives METHODS			
Objectives METHODS Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	P. 6-7
Objectives METHODS Eligibility criteria Information sources	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	P. 6-7 P. 7

2	
3	
4	
5	
6	
7	
/	
ð	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
32	
31	
24 25	
22	
30	
3/	
38	
39	
40	
41	
42	
43	
44	
45	
46	

1

Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	P. 7-8
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	P. 7-8
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	P. 7-8
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	P. 7-8
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	P. 7-8
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	P. 8
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	P. 9
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as $I^2$ , Kendall's $\tau$ )	P. 9
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	P. 9
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	N/A
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	P. 9
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	N/A

* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

# **BMJ Open**

# **Psychosocial factors at work and inflammatory markers:** protocol for a systematic review and meta-analysis

Journal:	BMJ Open
Manuscript ID	bmjopen-2018-022612.R2
Article Type:	Protocol
Date Submitted by the Author:	20-Jul-2018
Complete List of Authors:	Eguchi, Hisashi; Kitasato University School of Medicine, Department of Public Health Watanabe, Kazuhiro; The University of Tokyo, Department of Mental Health, Graduate School of Medicine Kawakami, Norito; The University of Tokyo, Department of Mental Health Ando, Emiko; Osaka University, Department of Social and Environmental Health, Division of Environmental Medicine and Population Sciences, Graduate School of Medicine Arima, Hideaki; The University of Tokyo, Department of Mental Health, Graduate School of Medicine Asai, Yumi; The University of Tokyo, Department of Mental Health, Graduate School of Medicine Inoue, Akiomi; Kitasato University School of Medicine, Department of Public Health Inoue, Reiko; Hitachi Automotive Systems Ltd Iwanaga, Mai; Graduate School of Medicine, The university of Tokyo, Department of Psychiatric Nursing Imamura, Kotaro; The University of Tokyo, Department of Mental Health, Graduate School of Medicine Kobayashi, Yuka; Honda Motor Co., Ltd. Nishida, Norimitsu; Kyoto Industrial Health Association Otsuka, Yasumasa; Faculty of Human Sciences, University of Tsukuba Sakuraya, Asuka; The University of Tokyo, Department of Mental Health, Graduate School of Medicine Tsuno, Kanami; Wakayama Medical University - Kimiidera Campus, Department of Hygiene, School of Medicine Shimazu, Akihito; College of Liberal Arts and Sciences, Kitasato University, Tsutsum, Akizumi; Kitasato University, Department of Public Health
<b>Primary Subject Heading</b> :	Occupational and environmental medicine
Secondary Subject Heading:	Immunology (including allergy)
Keywords:	Inflammation, Psychosocial factors at work, Cardiology < INTERNAL MEDICINE, Occupational health, Workplace, MENTAL HEALTH

1 2 3 4 5 6 7	SCHOLARONE [™] Manuscripts
8 9 10 11 12 13 14 15 16 17 18 19 20 21 20 21 22 23	
24 25 26 27 28 29 30 31 32 33 34 35 36 27	
37 38 39 40 41 42 43 44 45 46 47 48 49 50	
52 53 54	

1 Psychosocial factors at work and inflammatory markers: protocol for a 2 systematic review and meta-analysis

## Authors

Hisashi Eguchi^{1*}, Kazuhiro Watanabe^{2,3*}, Norito Kawakami², Emiko Ando⁴,
 Hideaki Arima², Yumi Asai², Akiomi Inoue¹, Reiko Inoue⁵, Mai Iwanaga⁶, Kotaro
 Imamura², Yuka Kobayashi⁷, Norimitsu Nishida⁸, Yasumasa Otsuka⁹, Asuka
 Sakuraya², Kanami Tsuno¹⁰, Akihito Shimazu¹¹, Akizumi Tsutsumi¹

- ¹Department of Public Health, Kitasato University School of Medicine,
   Sagamihara, Japan
- ²Department of Mental Health, Graduate School of Medicine, The University of
   Tokyo, Tokyo, Japan
- ¹⁴ ³The Japan Society for the Promotion of Science, Tokyo, Japan
- ¹⁵ ⁴Division of Environmental Medicine and Population Sciences, Department of
- Social and Environmental Medicine, Graduate School of Medicine, Osaka
   University, Osaka, Japan
- ¹⁸ ⁵Hitachi Automotive Systems, Ltd., Hitachinaka, Japan
- ⁶Department of Psychiatric Nursing, Graduate School of Medicine, The
   University of Tokyo, Tokyo, Japan
- ²¹ ⁷Honda Motor Co., Ltd., Tokyo, Japan
- 22 ⁸Kyoto Industrial Health Association, Kyoto, Japan
- ²³ ⁹Faculty of Human Sciences, University of Tsukuba, Tokyo, Japan
  - ¹⁰Department of Hygiene, School of Medicine, Wakayama Medical University,
- 25 Wakayama, Japan
  - ²⁶ ¹¹Center for Human and Sciences, College of Liberal Arts and Sciences,
  - 27 Kitasato University, Sagamihara, Japan
  - ²⁸ *HE and KW made equal contributions to this study.

# 30 Corresponding author

- 31 Akizumi Tsutsumi
- 32 Department of Public Health, Kitasato University School of Medicine, Japan
- 1-15-1 Kitasato, Minami-ku, Sagamihara-shi, Kanagawa 252-0374, Japan
- 34 E-mail address: akizumi@kitasato-u.ac.jp
- 35 Phone: +81-42-778-9352
- 36 Fax: +81-42-778-9257

1 2		
3 4		
5 6	37	Ward county 2.016 words
7 8	38	word count: 2,016 words
9 10		
11 12		
13 14		
15		
17		
19		
20		
22		
24 25		
26 27		
28 29		
30 31		
32 33		
34 35		
36 37		
38 39		
40 41		
42 43		
44 45		
46 47		
48 49		
50 51		
52 53		
54 55		
56 57		2
58 59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

## 39 Abstract

**INTRODUCTION:** Chronic inflammation may be a mediator for the development of cardiovascular disease (CVD), metabolic diseases, and psychotic and neurodegenerative disorders. Meta-analytic associations between work-related psychosocial factors and inflammatory markers have shown that work-related psychosocial factors could affect the flexibility and balance of the immune system. However, few systematic reviews or meta-analyses have investigated the association between work-related psychosocial factors and inflammatory markers. Based on prospective studies, the present investigation will conduct a comprehensive systematic review and meta-analysis of the association between work-related psychosocial factors and inflammatory markers. **METHODS AND ANALYSIS:** The systematic review and meta-analysis will include published studies identified from electronic databases (PubMed, EMBASE, PsycINFO, PsycARTICLES, Web of Science and Japan Medical Abstracts Society) according to recommendations of the Meta-analysis of Observational Studies in Epidemiology guideline. Inclusion criteria are studies that did the following: examined associations between work-related psychosocial factors and increased inflammatory markers; used longitudinal or prospective cohort designs; were conducted among workers; provided sufficient data for calculating odds ratios or relative risk with 95% confidence intervals; were published as original articles in English or Japanese; and were published up to the end of 2017. Study selection, data extraction, quality assessment, and statistical syntheses will be conducted by 14 investigators. Any inconsistencies or disagreements will be resolved through discussion. The quality of studies will be evaluated using the Risk of Bias Assessment Tool for Nonrandomized Studies. ETHICS AND DISSEMINATION: The investigation study will be based on 

published studies, so ethics approval is not required. The results of this study will
 be submitted for publication in a scientific peer-reviewed journal. The findings
 may be useful for assessing risk factors for increased inflammatory markers in
 the workplace and determining future approaches for preventing CVD, metabolic
 diseases, and psychotic and neurodegenerative disorders.
 TRIAL REGISTRATION NUMBER: PROSPERO CRD42018081553

72 (https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=81553).

75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 92 93	<ul> <li>This systematic review and meta-analysis will offer comprehensive understanding of the association between work-related psychosocial factor and inflammatory markers.</li> <li>The review will include a range of work-related psychosocial factors and focus on inflammatory markers.</li> <li>To ensure stronger evidence, the review will include only prospective studies.</li> <li>The findings of this review may be useful for assessing chronic inflammat as a risk factor for cardiovascular disease (CVD), metabolic diseases, and psychotic and neurodegenerative disorders in the workplace as well as for determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that material cardiovascular for the confounding factors that material cardiovascular for the confounding factors that material cardiovascular for the confounding factors for the confounding factors that material cardiovascular for the cardiovascular for the confounding factors that material cardiovascular for the cardiovascular for the confounding factors that material cardiovascular for the cardiovascular for the confounding factors that material cardiovascular for the cardiovascular</li></ul>
76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 92 93	<ul> <li>understanding of the association between work-related psychosocial factors and inflammatory markers.</li> <li>The review will include a range of work-related psychosocial factors and focus on inflammatory markers.</li> <li>To ensure stronger evidence, the review will include only prospective studies.</li> <li>The findings of this review may be useful for assessing chronic inflammat as a risk factor for cardiovascular disease (CVD), metabolic diseases, and psychotic and neurodegenerative disorders in the workplace as well as for determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that market as a risk factor state.</li> </ul>
77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 92 93	<ul> <li>and inflammatory markers.</li> <li>The review will include a range of work-related psychosocial factors and focus on inflammatory markers.</li> <li>To ensure stronger evidence, the review will include only prospective studies.</li> <li>The findings of this review may be useful for assessing chronic inflammat as a risk factor for cardiovascular disease (CVD), metabolic diseases, and psychotic and neurodegenerative disorders in the workplace as well as for determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that material cardiovascular for the statement of the stateme</li></ul>
78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 92 93	<ul> <li>The review will include a range of work-related psychosocial factors and focus on inflammatory markers.</li> <li>To ensure stronger evidence, the review will include only prospective studies.</li> <li>The findings of this review may be useful for assessing chronic inflammat as a risk factor for cardiovascular disease (CVD), metabolic diseases, and psychotic and neurodegenerative disorders in the workplace as well as for determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that matched the second secon</li></ul>
79 80 81 82 83 84 85 86 87 88 89 90 91 92 93	<ul> <li>The review will include a range of work-related psychosocial factors and focus on inflammatory markers.</li> <li>To ensure stronger evidence, the review will include only prospective studies.</li> <li>The findings of this review may be useful for assessing chronic inflammat as a risk factor for cardiovascular disease (CVD), metabolic diseases, and psychotic and neurodegenerative disorders in the workplace as well as for determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that matched as a results.</li> </ul>
80 81 82 83 84 85 86 87 88 89 90 91 92 93	<ul> <li>focus on inflammatory markers.</li> <li>To ensure stronger evidence, the review will include only prospective studies.</li> <li>The findings of this review may be useful for assessing chronic inflammat as a risk factor for cardiovascular disease (CVD), metabolic diseases, and psychotic and neurodegenerative disorders in the workplace as well as for determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that matches and particular disease (CVD) and particular diseases.</li> </ul>
81 82 83 84 85 86 87 88 89 90 91 92 92 93	<ul> <li>To ensure stronger evidence, the review will include only prospective studies.</li> <li>The findings of this review may be useful for assessing chronic inflammat as a risk factor for cardiovascular disease (CVD), metabolic diseases, and psychotic and neurodegenerative disorders in the workplace as well as for determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that matches the provide the terminant of the second structure of the terminant of terminant of the terminant of terminant of the terminant of t</li></ul>
82 83 84 85 86 87 88 89 90 91 92 93	<ul> <li>To ensure stronger evidence, the review will include only prospective studies.</li> <li>The findings of this review may be useful for assessing chronic inflammat as a risk factor for cardiovascular disease (CVD), metabolic diseases, and psychotic and neurodegenerative disorders in the workplace as well as for determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that matches the provide the results.</li> </ul>
83 84 85 86 87 88 89 90 91 91 92 93	<ul> <li>studies.</li> <li>The findings of this review may be useful for assessing chronic inflammat as a risk factor for cardiovascular disease (CVD), metabolic diseases, and psychotic and neurodegenerative disorders in the workplace as well as for determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that m</li> </ul>
84 85 86 87 88 89 90 91 92 92 93	<ul> <li>The findings of this review may be useful for assessing chronic inflammat as a risk factor for cardiovascular disease (CVD), metabolic diseases, an psychotic and neurodegenerative disorders in the workplace as well as for determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that metabolic diseases and the second sec</li></ul>
<ul> <li>85</li> <li>86</li> <li>87</li> <li>88</li> <li>89</li> <li>90</li> <li>91</li> <li>92</li> <li>93</li> </ul>	<ul> <li>The findings of this review may be useful for assessing chronic inflammat as a risk factor for cardiovascular disease (CVD), metabolic diseases, an psychotic and neurodegenerative disorders in the workplace as well as for determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that m</li> </ul>
86 87 88 89 90 91 92 93	<ul> <li>as a risk factor for cardiovascular disease (CVD), metabolic diseases, an psychotic and neurodegenerative disorders in the workplace as well as for determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that metabolic diseases.</li> </ul>
87 88 89 90 91 92 93	<ul> <li>psychotic and neurodegenerative disorders in the workplace as well as for determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that metabolic diseases.</li> </ul>
88 89 90 91 92 93	<ul> <li>determining future approaches for preventing CVD, metabolic diseases, a psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that maginal productions and preventions.</li> </ul>
89 90 91 92 93	<ul> <li>psychotic and neurodegenerative disorders.</li> <li>Depending on the results, limitations could be confounding factors that manual statements.</li> </ul>
90 91 92 93	<ul> <li>Depending on the results, limitations could be confounding factors that m</li> </ul>
91 92 93	<ul> <li>Depending on the results, limitations could be confounding factors that m</li> </ul>
92 93	
93	not have been adjusted for in the selected studies as well as low
	4

# 94 INTRODUCTION

Most adults spend around half of their waking hours at work, and so the workplace is an important setting to promote health and well-being. Increasing attention is being directed to work-related psychosocial factors, such as job strain,¹⁻⁵ effort-reward imbalance,⁶ organizational justice,⁷⁻⁹ and workplace social capital¹⁰; there is a major focus on work stress.² These factors may affect cardiovascular disease (CVD), metabolic diseases, and psychotic and neurodegenerative disorders through such mechanisms as prolonged overactivation and dysregulation of the autonomic nervous system and the hypothalamus-pituitary-adrenal cortex axis.11-13 

Chronic inflammation has been suggested as a potential mediator for the development of CVD, metabolic diseases, and psychotic and neurodegenerative disorders.¹⁴⁻¹⁸ Several studies have reported associations between adverse work-related psychosocial factors and increased levels of inflammatory markers. Inflammatory markers, including C-reactive protein (CRP),¹⁹⁻²⁴ interleukin-6 (IL-6),^{24 25} and tumor necrosis factor (TNF- $\alpha$ ), have been implicated in coordinating atherosclerosis.²⁶ Previous meta-analyses^{27 28} have identified the associations between psychosocial factors and inflammatory markers; however, the findings from those studies were not conclusive because of methodological heterogeneity (e.g., conceptualization or measurement of work-related psychosocial factors, sample compositions, and statistical approaches). 

Meta-analytic associations between work-related psychosocial factors and inflammatory markers indicate that such factors may affect the flexibility and balance of the immune system. Some meta-analyses have investigated inflammatory markers in relation to psychological stress²⁷⁻³⁰ and

unemployment³¹; however, few systematic reviews or meta-analyses have been conducted regarding the associations between work-related psychosocial factors and inflammatory markers. A systematic review of 56 studies by Nakata³² suggested that work-related psychosocial factors were related to disrupted immune response. However, that study did not statistically synthesize the associations. To our knowledge, only one meta-analysis of the association between effort-reward imbalance and inflammatory markers (k = 7, N = 9952) found a negative association with immunity (r = -0.09; confidence interval [CI], -0.14 to -0.05; P < 0.001).¹³ These systematic reviews and meta-analyses included cross-sectional studies. However, pooled associations between work-related psychosocial factors and inflammatory markers derived from 

1		
2		
3		
4 5	100	progrative studios may provide more reliable svidence
6	130	prospective studies may provide more reliable evidence.
7	131	Based on published prospective studies, the present investigation will
8	132	conduct a comprehensive systematic review and meta-analysis of the
9 10	133	associations between work-related psychosocial factors and inflammatory
11	134	markers. Inflammatory markers will include those that were previously
12	135	investigated in terms of associations with psychosocial factors at work, including
13 14	136	CRP, IL-6, and TNF- $\alpha$ . Our hypothesis is that adverse work-related psychosocial
15	137	factors would increase inflammatory markers. Moreover, we will identify the
16	138	work-related psychological factors that have the strongest associations with
17 18	139	specific inflammatory markers.
19	140	
20	141	METHODS AND ANALYSIS
21	141	Study design
23	142	This study protocol for a systematic review and mate analysis of
24	143	This study protocol for a systematic review and meta-analysis of
25	144	prospective studies follows the Preferred Reporting Items for Systematic
20 27	145	Reviews and Meta-Analysis Protocols guideline. ³³ Future findings will be
28	146	reported according to the Meta-analysis of Observational Studies in
29	147	Epidemiology (MOOSE) reporting guidelines. ³⁴ This study protocol was
30 31	148	registered with PROSPERO (CRD42018081553).
32	149	
33	150	Eligibility criteria
34 35	151	Participants, exposures, comparisons, and outcomes (PECO) of the
36	152	studies included in this systematic review and meta-analysis will be defined as
37	152	follows: (P) inclusion of all workers: (E) presence of adverse psychosocial
38	153	factors at work: (C) absonage of adverse psychosocial factors at work: and (C)
39 40	154	increase ad influence store marketer. To not a perticipante will all be appalence of
41	155	increased inflammatory markers. Target participants will all be employees of
42	156	participating companies. There will be no exclusion criteria related to
43 44	157	employment status, job type, or shift type. The study exposures (adverse
45	158	psychosocial factors at work) will include a range of task and organizational
46	159	characteristics and work conditions, ³⁵ such as job strain, ¹⁻⁵ low social support,
47 48	160	effort-reward imbalance, ⁶ organizational injustice, ⁷⁻⁹ and low workplace social
49	161	capital. ¹⁰ Long working hours and shift work will also be included as target
50	162	exposures. Inflammatory markers will include those investigated in terms of
51 52	163	association with psychosocial factors at work in previous studies, including CRP.
52 53	164	$II_{-6}$ and TNF- $\alpha$
54	104	Eligibility criteria for selection are the following studies that (1) were
55	105	
56 57		C
58		ΰ
59		

conducted to evaluate associations between psychosocial factors at work and inflammatory markers; (2) used longitudinal or prospective cohort designs; (3) were conducted among workers; (4) provided sufficient data for calculating coefficients of associations between psychosocial factors at work and inflammatory markers ( $\gamma$ ,  $\beta$ ), odds ratios (ORs), relative risks (RRs), or hazard ratios (HRs) with standard errors (SEs) or 95% CIs; (5) were published as original articles in English or Japanese; and (6) were published up to the end of 2017. 

### 175 Information sources, search strategy, and data management

A systematic search of published studies will be conducted using electronic databases: PubMed (MEDLINE), EMBASE, PsycINFO, PsycARTICLES, Web of Science, and the Japan Medical Abstracts Society. Search terms will include words related to the PECO of eligible published studies. The proposed search strategy appears in Appendix 1. All identified studies will be managed in a Microsoft Excel file (WA, US). Before the study selection process, duplicated citations in the Excel file will be excluded by KW. Decisions on all studies will be recorded.

#### 185 Study selection process

First, following the eligibility criteria, 14 investigators (HE, KW, EA, HA, YA, AI, RI, MI, KI, YK, NN, YO, ASa, and KT) will independently conduct screening of identified titles and abstracts in pairs. Second, we will obtain full texts of all eligible studies. In the full-text review phase, the studies will be examined using a standardized form (Appendix 2) to assess eligibility for inclusion in this review. The number of papers examined by each investigator will depend on the investigator's capacity. Any discrepancies in assessment will be recorded and the inter-rater reliability determined; such matters will be discussed among all the investigators until consensus is reached. We will directly contact the corresponding authors of eligible studies if the results of the publication are unclear and may be related to multiple interpretations or if the reported results did not show data relevant to our study analysis. The reasons for excluding studies will be recorded. A flow chart will be prepared showing the entire review process. 

#### 201 Data extraction

Data will be extracted independently from the included studies by 14 investigators (HE, KW, EA, HA, YA, AI, RI, MI, KI, YK, NN, YO, ASa, and KT) working in pairs using a standardized data extraction form. The data will be distributed according to the investigators' capacity. Any discrepancies or inconsistencies in the assessment will be recorded and the inter-rater reliability determined; such matters will be discussed among all the investigators until consensus is reached. The extracted data will include the following: year of publication; country where the study was conducted; number of participants at baseline and in the analysis; sampling framework; participants' demographic characteristics (i.e., mean age, sex proportions, and employment status); length of follow-up; follow-up rate; exposure and comparison variables (adverse psychosocial factors at work); outcome variables (inflammatory markers); number and proportion of participants with increased levels of inflammatory markers or mean scores and variances or standard deviations of markers; and sufficient data for calculating the coefficients ( $\beta$ ,  $\gamma$ ), ORs, RRs, or HRs with SEs or 95% CIs for the association between adverse psychosocial factors at work and inflammatory markers. If the included studies report multiple measures of association, we will attempt to select measures of association adjusted by demographic variables (e.g., age, sex, education, and marital status). If the studies report measures of association adjusted by lifestyle variables (e.g., smoking, physical activity, and sleep), we will as far as possible extract measures both with and without adjustment for lifestyle variables. To avoid over-adjustment, measures of association adjusted for other adverse psychosocial factors at work or inflammatory markers will not be adopted. Sex-stratified coefficients will be selected if they are the only reported results. Any missing data from the studies will be obtained by contacting the relevant research team.

#### 230 Assessment of study quality

Fourteen investigators (HE, KW, EA, HA, YA, AI, RI, MI, KI, YK, NN, YO, ASa, and KT) will independently assess in pairs the quality of each included study using the internationally recognized Risk of Bias Assessment Tool for Nonrandomized Studies (RoBANS).^{36 37} The RoBANS was developed to determine the risk of bias of non-randomized studies; it comprises six domains: selection of participants; confounding variables; measurement of exposure; blinding of outcomes; incomplete outcome data; and selective outcome reporting.

The risk of bias for each domain is classified as low, high, or unclear risk. The number of papers assessed by each investigator will depend on their capacity. Any discrepancies in quality assessment among the investigators will be recorded and the inter-rater reliability determined; such matters will be discussed among all the investigators until consensus is reached.

## 244 Data synthesis and statistical methods

The included studies will be statistically synthesized in a meta-analysis to estimate pooled coefficients and 95% CIs, stratified by types of measures of association ( $\beta$ ,  $\gamma$ , OR, RR, and HR). If the included studies report ORs, RRs, or HRs, we will calculate log-transformed ORs, RRs, or HRs and determine SEs based on 95% CIs. These parameters will be used in the meta-analysis and for examining publication bias by means of a funnel plot and Egger's test with statistical software, R version 3.4.1.38 39 We will employ a random-effects model⁴⁰ to summarize the results using R version 3.4.1 with the "meta" and "metafor" packages.41 

For the main analysis, we will synthesize all types of psychosocial factors at work in the random-effects model. The results will be presented in a narrative format if a meta-analysis is not appropriate or possible, e.g., if only two or fewer studies are eligible and included in the study. Heterogeneity will be assessed using the chi-square test with Cochran's *Q* statistic, which is calculated by  $l^2$ values,⁴² assuming that  $l^2$  values of 25%, 50%, and 75% indicate low, medium, and high heterogeneity, respectively.

Subgroup and sensitivity analyses will be conducted to compare the results across subgroups or under specific conditions when sufficient heterogeneity is detected. Major possible grouping characteristics will include types of exposure and outcome, participants' demographic characteristics (e.g., sex, age, employment status, occupational groups), and study guality. Any subgroup differences will be reported, and our findings will be explained by considering these differences. Results with and without adjustment for lifestyle variables will be compared in another sensitivity analysis. If trends are observed between pooled associations and any grouping characteristics, meta-regression will be conducted using the "metareg" function of R. A sensitivity analysis may be conducted for included studies where the RoBANS is classified as low risk. All extracted data and analyzed results will be deposited by the corresponding author and made available for external reviewers and readers upon request. 

2		
3		
5	274	
6	275	Patient and public involvement statement
/	276	This study will not involve any patients or study participants: this study
9	210	protocol is for a systematic review and meta analysis
10	211	protocor is for a systematic review and meta-analysis.
11	278	
12	279	Ethics and dissemination
14	280	This study does not require ethical approval because the systematic review and
15	281	meta-analysis will be based on previously published studies. The results will be
16 17	282	submitted for publication in a scientific peer-reviewed journal, according to the
17	283	MOOSE guideline. ³⁴
19	284	
20	285	Funding
21	200	This work is supported by the Work-related Diseases Clinical Research Grant
23	200	2016 (160701 01) from the Ministry of Health Labour and Wolfers, Japan. The
24	287	
25	288	funder has no role in study design, data extraction and analysis, decision to
20	289	publish, or preparation of the final manuscript.
28	290	
29	291	Competing Interests
30 31	292	The authors declare that they have no competing interests.
32	293	
33	294	Strengths and limitations
34	295	This systematic review and meta-analysis will be based on prospective studies
36	296	and show the strongest evidence for the associations between psychosocial
37	200	factors at work and inflammatory markers. The findings will highlight potential
38	291	ractors at work and minaminatory markers. The mindings will highlight potential
40	298	mediators and underlying mechanisms for the development of CVD owing to
41	299	adverse psychosocial factors.
42	300	There are several likely limitations in this study, including confounding
43 44	301	bias and low generalizability. If selected studies do not report
45	302	demographic-adjusted associations, the findings will be distorted by the
46	303	unobserved characteristics among the population. In addition, the findings will
47	304	not be generalizable to populations not included in the selected studies.
40 49	305	
50	306	Authors' contributions
51	307	HE KW NK EA HA YA AL RI MI KI YK NN YO ASa KT ASh and AT
52 53	200	made substantial contributions to the concention and design of the study writing
54	308	the protocol and rouising it critically for important intelligence as the
55	309	the protocol and revising it critically for important intellectual content, and
56 57		
58		10
59		

310	app	proving the final version to be published. All authors will be involved in the
311	ent	ire study process (i.e., data extraction, assessment, and synthesis).
312		
313	Ac	knowledgements
314	We	e thank Audrey Holmes, MA, from Edanz Group (www.edanzediting.com/ac)
315	for	editing a draft of this manuscript.
316		
317	Re	ferences
318	1.	Kivimaki M, Nyberg ST, Batty GD, et al. Job strain as a risk factor for
319		coronary heart disease: a collaborative meta-analysis of individual
320		participant data. <i>Lancet</i> 2012;380:1491–7.
321		doi:10.1016/s0140-6736(12)60994-5
322	2.	Kivimaki M, Kawachi I. Work stress as a risk factor for cardiovascular
323		disease. Curr Cardiol Rep 2015;17:630. doi: 10.1007/s11886-015-0630-8
324	3.	Fishta A, Backe EM. Psychosocial stress at work and cardiovascular
325		diseases: an overview of systematic reviews. Int Arch Occup Environ Health
326		2015;88:997–1014. doi:10.1007/s00420-015-1019-0
327	4.	Theorell T, Karasek RA. Current issues relating to psychosocial job strain
328		and cardiovascular disease research. <i>J Occup Health Psychol</i> 1996;1:9–26.
329	5.	Belkic KL, Landsbergis PA, Schnall PL, et al. Is job strain a major source of
330		cardiovascular disease risk? Scand J Work Environ Health 2004;30:85–128.
331	6.	Siegrist J. Adverse health effects of high-effort/low-reward conditions. J
332		Occup Health Psychol 1996;1:27–41.
333	7.	De Vogli R, Ferrie JE, Chandola T, et al. Unfairness and health: evidence
334		from the Whitehall II Study. <i>J Epidemiol Community Health</i> 2007;61:513–8.
335		doi:10.1136/jech.2006.052563
336	8.	Elovainio M, Leino-Arjas P, Vahtera J, et al. Justice at work and
337		cardiovascular mortality: a prospective cohort study. J Psychosom Res
338		2006;61:271–4. doi:10.1016/j.jpsychores.2006.02.018
339	9.	Kivimaki M, Ferrie JE, Brunner E, et al. Justice at work and reduced risk of
340		coronary heart disease among employees: the Whitehall II Study. Arch
341		Intern Med 2005;165:2245–51. doi:10.1001/archinte.165.19.2245
342	10.	Oksanen T, Kawachi I, Jokela M, et al. Workplace social capital and risk of
343		chronic and severe hypertension: a cohort study. J Hypertens
344		2012;30:1129–36. doi:10.1097/HJH.0b013e32835377ed
345	11.	Kivimaki M, Virtanen M, Elovainio M, et al. Work stress in the etiology of
		11

3		
4		
6	346	coronary heart disease—a meta-analysis. Scand J work Environ Health
7	347	2006;32:431–42.
8	348	12. Barth J, Schneider S, von Kanel R. Lack of social support in the etiology and
9 10	349	the prognosis of coronary heart disease: a systematic review and
11	350	meta-analysis. Psychosom Med 2010;72:229–38.
12	351	doi:10.1097/PSY.0b013e3181d01611
13	352	13. Eddy P, Heckenberg R, Wertheim EH, et al. A systematic review and
15	353	meta-analysis of the effort-reward imbalance model of workplace stress with
16 17	354	indicators of immune function. J Psychosom Res 2016;91:1–8.
18	355	doi:10.1016/j.jpsychores.2016.10.003
19	356	14. Lopez-Candales A, Hernandez Burgos PM, Hernandez-Suarez DF, et al.
20	357	Linking chronic inflammation with cardiovascular disease: From normal
22	358	aging to the metabolic syndrome. J Nat Sci 2017;3:e341.
23	359	15 Siegrist J. Li.J. Work stress and altered biomarkers: A synthesis of findings
24 25	360	based on the effort-reward imbalance model. Int. I Environ Res Public Health
26	261	2017:14:1373 doi: 10.3300/ijerob14111373
27	269	16 Polaton IC Lyons CL Konnedy EP at al. Eatty saids and NL PP3
28 29	302	inflormonome mediated inflormation in metabolic ticcurs. Annu Day Nutr
30	363	Innammasome-mediated innammation in metabolic tissues. Annu Rev Nutr
31	364	2017;37:77–102. doi: 10.1146/annurev-nutr-071816-064836
32	365	17. Singh B, Chaudhuri TK. Role of C-reactive protein in schizophrenia: an
34	366	overview. <i>Psychiatry Res</i> 2014;216:277-85. doi:
35	367	10.1016/j.psychres.2014.02.004
36	368	18. Dopkins N, Nagarkatti PS, Nagarkatti M. The role of gut microbiome and
38	369	associated metabolome in the regulation of neuroinflammation in multiple
39	370	sclerosis and its implications in attenuating chronic inflammation in other
40	371	inflammatory and autoimmune disorders. Immunology 2018 (in press) doi:
41	372	10.1111/imm.12903
43	373	19. Equchi H, Shimazu A, Kawakami N, et al. Source-specific workplace social
44	374	support and high-sensitivity C-reactive protein levels among Japanese
45 46	375	workers: A 1-year prospective cohort study. Am J Ind Med 2016:59:676–84
47	376	doi:10.1002/aiim 22600
48	277	20 Tsai SS Lai CH Shih TS et al High ion strain is associated with
49 50	270	inflormatory markers of diagona in young long hould bue drivers. / Occur
51	378	
52	379	Health Psychol 2014;19:336–47. doi:10.1037/a0036600
53 54	380	21. Emeny R, Lacruz ME, Baumert J, et al. Job strain associated CRP is
55	381	mediated by leisure time physical activity: results from the MONICA/KORA
56 57		
58		12
59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

382	study. Brain Behav Immun 2012;26:1077–84. doi:10.1016/j.bbi.2012.07.004	1
383	22. Xu W, Chen B, Guo L, et al. High-sensitivity CRP: possible link between job	)
384	stress and atherosclerosis. Am J Ind Med 2015;58:773–9.	
385	doi:10.1002/ajim.22470	
386	23. Almadi T, Cathers I, Hamdan Mansour AM, et al. The association between	
387	work stress and inflammatory biomarkers in Jordanian male workers.	
388	<i>Psychophysiology</i> 2012;49:172–7. doi:10.1111/j.1469-8986.2011.01296.x	
389	24. Elovainio M, Ferrie JE, Singh-Manoux A, et al. Organisational justice and	
390	markers of inflammation: the Whitehall II study. Occup Environ Med	
391	2010;67:78–83. doi:10.1136/oem.2008.044917	
392	25. Nakata A, Irie M, Takahashi M. Source-specific social support and circulatin	g
393	inflammatory markers among white-collar employees. Ann Behav Med	
394	2014;47:335–46. doi:10.1007/s12160-013-9555-x	
395	26. Ridker PM, Luscher TF. Anti-inflammatory therapies for cardiovascular	
396	disease. <i>Eur Heart J</i> 2014;35:1782–91. doi:10.1093/eurheartj/ehu203	
397	27. Herbert TB, Cohen S. Stress and immunity in humans: a meta-analytic	
398	review. <i>Psychosom Med</i> 1993;55:364–79.	
399	28. Segerstrom SC, Miller GE. Psychological stress and the human immune	
400	system: a meta-analytic study of 30 years of inquiry. Psychol Bull	
401	2004;130:601–30. doi:10.1037/0033-2909.130.4.601	
402	29. Steptoe A, Hamer M, Chida Y. The effects of acute psychological stress on	
403	circulating inflammatory factors in humans: A review and meta-analysis.	
404	Brain Behav Immun 2007;21:901–12. doi:10.1016/j.bbi.2007.03.011	
405	30. Marsland AL, Walsh C, Lockwood K, et al. The effects of acute psychologica	al
406	stress on circulating and stimulated inflammatory markers: A systematic	
407	review and meta-analysis. Brain Behav Immun 2017;64:208–19.	
408	doi:10.1016/j.bbi.2017.01.011	
409	31. Hughes A, Kumari M, McMunn A, et al. Unemployment and inflammatory	
410	markers in England, Wales and Scotland, 1998–2012: Meta-analysis of	
411	results from 12 studies. Brain Behav Immun 2017;64:91–102.	
412	doi:10.1016/j.bbi.2017.03.012	
413	32. Nakata A. Psychosocial job stress and immunity: A systematic review. In:	
414	Yan Q, ed. Psychoneuroimmunology: Methods and Protocols. Totowa, NJ:	
415	Humana Press 2012:39–75.	
416	33. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for	
417	systematic review and meta-analysis protocols (PRISMA-P) 2015 statemen	t.
	13	

2		
3		
4		
5	418	Systematic Reviews 2015;4:1. doi:10.1186/2046-4053-4-1
6 7	419	34. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational
8	420	studies in epidemiology: a proposal for reporting. Meta-analysis Of
9	421	Observational Studies in Epidemiology (MOOSE) group. JAMA
10 11	422	2000;283:2008–12.
12	423	35. Semmer NK. Job stress interventions and the organization of work. Scand J
13 14	424	Work. Environ Health 2006;32(6):515–27.
14	425	36. Kim SY. Park JE. Lee YJ. et al. Testing a tool for assessing the risk of bias
16	426	for nonrandomized studies showed moderate reliability and promising
17 18	427	validity J Clin Epidemiol 2013;66:408-14 doi: 10.1016/i.iclineni.2012.09.016
19	428	Inublished Online First: 2013/01/23
20	120	
21	429	37. Wells G, Shea B, O'Connell D. The Newcastle-Ottawa Scale (NOS) for
22	430	assessing the quality of nonrandomized studies in meta-analyses.
24	431	Secondary The Newcastle-Ottawa Scale (NOS) for assessing the quality of
25	432	nonrandomised studies in meta-analyses, 2014. Available from:
26 27	433	http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
28	434	38. Watanabe K, Imamura K, Kawakami N. Working hours and the onset of
29	435	depressive disorder: a systematic review and meta-analysis. Occup Environ
30 31	436	Med 2016;73:877–84. doi:10.1136/oemed-2016-103845
32	437	39. Sakuraya A, Watanabe K, Kawakami N, et al. Work-related psychosocial
33	438	factors and onset of metabolic syndrome among workers: a systematic
34 35	439	review and meta-analysis protocol. BMJ Open 2017;7:e016716.
36	440	doi:10.1136/bmiopen-2017-016716
37	441	40. Hunter JE. Schmidt FL. Fixed effects vs. random effects meta-analysis
39	442	models: Implications for cumulative research knowledge. Int J Sel Assess
40	443	2000:8:275–92 doi:10.1111/1468-2389.00156
41	110	41 Team RC R: A language and environment for statistical computing Vienna
42	445	Austria: D Equipation for Statistical Computing: 2014
44	440	Austina. R Foundation for Statistical Computing, 2014.
45	446	42. Higgins J, Thompson SG. Quantifying neterogeneity in a meta-analysis. Stat
46 47	447	<i>Med</i> 2002;21:1539–58.
48		
49		

# Appendix 1. Search terms used for the electronic databases

Database	Search terms
PubMed	(employe*[tw] OR manag*[tw] OR colleague*[tw] OR worksit*[tw] OR "work"[tw] OR works*[tw] OR work *[tw] OR
	worka*[tw] OR worke*[tw] OR workg*[tw] OR worki*[tw] OR workl*[tw] OR workp*[tw] OR occupant*[tw] OR company*[tw]
	OR offic*[tw] OR busines*[tw] OR workplace[mh]) AND
	(("Stress, Mechanical"[Mesh] OR "Lifting"[Mesh] OR "Moving and Lifting Patients"[Mesh] OR "Weight-Bearing"[Mesh] OR
	"Biomechanics" OR "Physical Exertion" [Mesh] OR "Torsion, Mechanical" [Mesh] OR "Postural Balance" [Mesh] OR
	"Walking"[Mesh] OR "Recovery of Function"[Mesh] OR "Relaxation"[Mesh] OR (static[Title/Abstract] AND posture) OR
	(awkward[Title/Abstract] AND posture) OR (dynamic[Title/Abstract] AND posture) OR static work[Title/Abstract] OR dynamic
	load*[Title/Abstract] OR lift*[Title/Abstract] OR carry*[Title/Abstract] OR hold*[Title/Abstract] OR pull*[Title/Abstract] OR
	drag*[Ittle/Abstract] OR push*[Ittle/Abstract] OR manual nandling[Ittle/Abstract] OR force*[Ittle/Abstract] OR
	biomechanic*[Inte/Abstract] OR waiking*[Inte/Abstract] OR postural balance[Inte/Abstract] OR inexion*[Inte/Abstract] OR systemation*[Inte/Abstract] OR syst
	squetting[Title/Abstract] OP twisting[Title/Abstract] OP bending[Title/Abstract] OP reaching[Title/Abstract] OP
	squarting[Title/Abstract] OR isologi Title/Abstract] OR bending[Title/Abstract] OR repetitive movement*[Title/Abstract] OR monotonous
	work[Title/Abstract] OR relayation[Title/Abstract] OR recovery of function[Title/Abstract] OR nbysical demand*[Title/Abstract]
	OR physically demand*[Title/Abstract]) OR ("Stress, Psychological"[Mair] OR "Social Support"[Mair] OR "Job
	Satisfaction"[Mesh] OR "Work Schedule Tolerance"[Mesh] OR "Employee Performance Appraisal"[Mesh] OR "Employee
	Grievances" [Mesh] OR "Social Justice/psychology" [Mesh] OR "Personnel Downsizing" [Mesh] OR "Staff Development" [Mesh]
	OR "Organizational Culture" [Mesh] OR "Bullying" [Mesh] OR "Prejudice" [Mesh] OR "Social Discrimination" [Mesh] OR
	"Interpersonal Relations" [Mesh] OR "Communication/psychology" [Mesh]) OR (psychosocial [Title/Abstract] OR job
	strain[Title/Abstract] OR work strain[Title/Abstract] OR work demand*[Title/Abstract] OR job demand*[Title/Abstract] OR high
	demand*[Title/Abstract] OR low control[Title/Abstract] OR lack of control[Title/Abstract] OR work control[Title/Abstract] OR job
	control[Title/Abstract] OR decision latitude[Title/Abstract] OR work influence*[Title/Abstract] OR demand
	resource*[Title/Abstract] OR effort reward*[Title/Abstract] OR time pressure*[Title/Abstract] OR recuperation*[Title/Abstract]
	OR work overload*[Title/Abstract] OR work over-load*[Title/Abstract] OR recovery[Title/Abstract] OR coping[Title/Abstract]
	OR work ability[Title/Abstract] OR social support[Title/Abstract] OR support system*[Title/Abstract] OR social
	network*[Title/Abstract] OR emotional support[Title/Abstract] OR interpersonal relation*[Title/Abstract] OR
	interaction*[Title/Abstract] OR social capital [Title/Abstract] OR justice*[Title/Abstract] OR injustice*[Title/Abstract] OR job
	satisfaction[Title/Abstract] OR work satisfaction[Title/Abstract] OR boredom[Title/Abstract] OR skill discretion*[Title/Abstract]
	OK staff development[11tle/Abstract] OK discrimination[11tle/Abstract] OK harass*[11tle/Abstract] OR work-place

	conflict*[Title/Abstract] OR workplace violen*[Title/Abstract] OR work-place violen*[Title/Abstract] OR bullying[Title/Abstract] OR ageism[Title/Abstract] OR homophobia[Title/Abstract] OR racism[Title/Abstract] OR sexism[Title/Abstract] OR victimization*[Title/Abstract] OR silent workplace*[Title/Abstract] OR role ambiguity[Title/Abstract] OR role- conflict*[Title/Abstract] OR work-role*[Title/Abstract] OR working hour*[Title/Abstract] OR working time[Title/Abstract] OR day-time[Title/Abstract] OR night-time[Title/Abstract] OR shift work*[Title/Abstract] OR work shift*[Title/Abstract] OR temporary work[Title/Abstract] OR full-time[Title/Abstract] OR part-time[Title/Abstract] OR flexible work*[Title/Abstract] OR organizational change[Title/Abstract] OR organisational change[Title/Abstract] OR lean production[Title/Abstract] OR job security[Title/Abstract] OR job insecurity[Title/Abstract])) AND ((("inflammation"[MeSH Terms] OR inflammation*[All Fields]) OR ("immune system"[MeSH Terms] OR "immune system"]
	phenomena" [MeSH Terms] OR "immunity" [All Fields] OR "immunology" [All Fields])) OR ("c-reactive protein" [MeSH Term OR ("c-reactive" [All Fields] AND protein [All Fields]) OR c-reactive protein [All Fields] OR CRP[All Fields]) OR ("cytokines" [MeSH Terms] OR cytokine* [All Fields]) OR ("lymphokines" [MeSH Terms] OR lymphokine* [All Fields]) OR ("chemokines" [MeSH Terms] OR chemokine* [All Fields]) OR ("immonokines" [MeSH Terms] OR monokine* [All Fields]) OR ("tumor necrosis factor-alpha" [MeSH Terms] OR tumor necrosis factor* [All Fields] OR ("tumor" [All Fields] AND "necrosis Fields] AND factor* [All Fields]) OR TNF* [All Fields]) OR ("interleukins" [MeSH Terms] OR interleukin* [All Fields] OR IL Fields])) AND ((longitudinal stud*) OR (prospective cohort stud*) OR (prospective stud*) OR (follow-up stud*) OR (observational stud*) OR (externational stud*) OR (cohort stud*) OR (criminal cohort stud*) OR (cohort stud*
EMBASE,	(employe* OR manag* OR colleague* OR worksit* OR "work" OR works* OR work* OR worka* OR worke* OR workg* (
PsycINFO/ PsycARTICLES , Web of Science	worki* OR workl* OR workp* OR occupant* OR company* OR offic* OR busines* OR workplace) AND (("Stress, Mechanical" OR "Lifting" OR "Moving and Lifting Patients" OR "Weight-Bearing" OR "Biomechanics" OR "Phys Exertion" OR "Torsion, Mechanical" OR "Postural Balance" OR "Walking" OR "Recovery of Function" OR "Relaxation" OR (static AND posture) OR (awkward AND posture) OR (dynamic AND posture) OR (static AND work) OR (dynamic AND loa OR lift* OR carry* OR hold* OR pull* OR drag* OR push* OR (manual AND handling) OR force* OR biomechanic* OR walking* OR (postural AND balance) OR flexion* OR extension* OR turning OR sitting OR kneeling OR squatting OR twis OR bending OR reaching OR standing OR sedentary OR (repetitive AND movement*) OR (monotonous AND work) OR relaxation OR (recovery AND of AND function) OR (physical AND demand*) OR (physically AND demand*)) OR ("Stress, Psychological"/exp OR "Stress, Psychological" OR "Social Support"/exp OR "Social Support" OR "Job Satisfaction"/exp OR Satisfaction" OR "Work Schedule Tolerance"/exp OR "Work Schedule Tolerance" OR "Employee Performance Appraisal"/ex "Employee Performance Appraisal" OR "Employee Grievances"/exp OR "Employee Grievances" OR "Social Justice/psychol OR "Personnel Downsizing"/exp OR "Personnel Downsizing" OR "Social Discrimination"/exp OR "Bullying" OR "Prejudice"/exp OR "Prejudice"/exp OR "Prejudice" OR "Social Discrimination"/exp OR "Bullying" OR "Prejudice"/exp OR

	OR (work AND control) OR (job AND control) OR (decision AND latitude) OR (work AND influence*) OR (demand AND
	resource*) OR (effort AND reward*) OR (time AND pressure*) OR recuperation* OR (work AND overload*) OR (work AND
	over-load*) OR recovery OR coping OR (work AND ability) OR (social AND support) OR (support AND system*) OR (social
	AND network*) OR (emotional AND support) OR (interpersonal AND relation*) OR interaction* OR (social AND capital) OR
	justice* OR injustice* OR (job AND satisfaction) OR (work AND satisfaction) OR boredom OR (skill AND discretion*) OR (staff
	AND development) OR discrimination OR harass* OR (work-place AND conflict*) OR (workplace AND violen*) OR (workplace
	AND violen*) OR bullying OR ageism OR homophobia OR racism OR sexism OR victimization* OR (silent AND workplace*)
	OR (role AND ambiguity) OR role-conflict* OR work-role* OR (working AND hour*) OR (working AND time) OR day-time OR
	night-time OR (shift AND work*) OR (work AND shift*) OR (temporary AND work) OR full-time OR part-time OR (flexible
	AND work*) OR (organizational AND change) OR (organizational AND change) OR (lean AND production) OR (job AND
	security) OR (job AND insecurity))) AND
	((("inflammation" OR inflammation*) OR ("immune system" OR "immune system phenomena" OR "immunity" OR
	"immunology")) OR ("c-reactive protein" OR ("c-reactive" AND protein) OR c-reactive protein OR CRP) OR ("cytokines" OR
	cytokine*) OR ("lymphokines" OR lymphokine*) OR ("chemokines" OR chemokine*) OR ("monokines" OR monokine*) OR
	("tumor necrosis factor-alpha" OR tumor necrosis factor* OR ("tumor" AND "necrosis" AND factor*) OR TNF*) OR
	("interleukins" OR interleukin* OR IL)) AND
	((longitudinal stud*) OR (prospective cohort stud*) OR (prospective stud*) OR (follow-up stud*) OR (observational stud*) OR
	(case-control stud*) OR (cohort stud*) OR (epidemiologic stud*) OR (cohort analy*) OR (observ* stud*) OR (retrospective stud*)
Japan Medical	(労働 OR 従業員 OR 社員 OR リークサンノル OR 同僚 OR 仲間 OR 上可 OR 管理 OR 監督 OR マイーンヤー
Abstracts	ORマネシャー OR 課長 OR 部長 OR 主任 OR 上長 OR 役員 OR チーブ OR リーター OR 上役 OR 雇い主 OR
Society	雇主 OR 雇用 OR ワークグループ OR 仕事 OR ワーク OR 作業 OR 就労 OR 勤務 OR ワーキング OR 働く OR
	職場 OR オフィス OR 研究所 OR 診療所 OR 医院 OR 事業 OR 職業 OR 家業 OR 事務 OR 業務 OR 執務 OR
	営業 OR 所業 OR 実業 OR 産業 OR 就業 OR 企業 OR 会社 OR 商会 OR 法人)AND
	(機械的ストレス OR 持ちあげ OR 患者の移動 OR 患者の持ち上げ OR 荷重負荷 OR 体重負荷 OR 生物力学 OR
	労作 OR 機械的ねじれ OR 姿勢 OR バランス OR ウォーキング OR 歩行 OR 機能的回復 OR リラクセーション
	OR 静的姿勢 OR 窮屈な姿勢 OR 動的姿勢 OR 静的労働 OR 動的負荷 OR 持ちあげ OR 運搬 OR 抱え込み OR
	引き OR 引きずり OR 押し OR 手作業 OR 力 OR 生物力学 OR ウォーキング OR 歩行 OR 姿勢 OR バランス
	OR 屈曲 OR 伸長 OR 拡張 OR 回転 OR 座位 OR 座り OR 膝曲げ OR スクワット OR より合わせ OR 曲げ
	OR 伸げし OR 立位 OR 应位 OR 反復運動 OR 単調動作 OR 単調か仕事 OR リラクセーション OR 機能的回復
	OR 身体的負荷 OR 身体的 OR 負荷) OR (心理的ストレス OR ソーシャル・サポート OR 仕事の満足度 OR 仕事
	ON 多体的复数 ON 多体的 ON 真物 ON (紀述的ハーレハ ON ) ション (ルーク の 日本の 他定) ON 日本 のフトレス耐姓 OP 従業員のパフェーマンス 評価 OP 従業員の 伝達 OP (社会的工業 AND 心理学) OP 人員削減
	ON T Y A M T Y A Y Y A Y Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y A T Y Y A T Y Y A T Y Y A T Y Y A T Y Y Y
	UN W未貝教目 UN 組織文化 UN いしめ UN 細兄 UN 社会的左肋 UN 対人関係 UN (コミュークーンヨン AND と畑学)) OD (と畑社会的 OD 仕事のストレイン OD 仕事のストレス OD 仕事の要告席 OD 方い要告席 OD がいこう
	心理子川UK (心理住会的 UK 住事のストレイン UK 住事のストレス UK 住事の要求度 OR 高い要求度 OR 低いコ

 ントロール OR コントロールの欠如 OR 仕事のコントロール OR 裁量の範囲 OR 仕事の影響 OR 要求度資源 OR 努力報酬 OR 時間的切迫 OR 病気からの回復 OR 療養 OR 仕事の負担 OR 回復 OR コーピング OR 対処 OR 職務能力 OR 社会的支援 OR ソーシャルサポート OR 支援システム OR サポートシステム OR 社会的ネットワー クOR ソーシャルネットワーク OR ソーシャルキャピタル OR 情緒的支援 OR 情緒的サポート OR 対人関係 OR 人間関係 OR 対人交流 OR 相互作用 OR 公正 OR 不公正 OR 職務満足感 OR 遺屈 OR 技能の幅 OR 職員研修 OR 差別 OR 嫌がらせ OR 職場の葛藤 OR 職場の暴力 OR いじめ OR 年齢差別 OR 同性愛差別 OR 人種差別 OR 性差別 OR 虐待 OR 静かな職場 OR 役割曖昧さ OR 役割葛藤 OR 仕事での役割 OR 労働時間 OR 勤務時間 OR 日中 OR 夜間 OR シフト業務 OR 交代勤務 OR 時間差勤務 OR 臨時業務 OR フルタイム OR パートタイム OR フレックス制度 OR 組織改革 OR 組織再編 OR リーン生産 OR トヨタ生産方式 OR 安定雇用 OR 不安定雇 用)AND (炎症 OR 免疫 OR C反応性 OR CRPOR サイトカイン OR リンホカイン OR ケモカイン OR モノカイン OR 腫瘍 壊死性因子 OR TNF ORインターロイキン OR IL)AND (縦断研究 OR 前向きコホート研究 OR 前向き研究 OR 追跡研究 OR フォローアップ研究 OR 観察研究 OR 症例 対照研究 OR 疲労研究 OR 後向き研究)

evien only

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

# Appendix 2. Standardized form to assess eligibility for inclusion

ID Database No	o Title	Author name	Source	Abstract	URL reviewe	er 1 reviewer 2	Result_ screening 1	Result_ screening 2	Result_ discussion
1 Embase	Effect of breastfeeding on postpartum 1 depressive symptoms among adolescent and young adult mothers	Sipsma H.L., Ruiz E., Jones K., Magriples U Kershaw T.,	Journal of Maternal-Fetal and Neonata Medicine (2018) 31:11 (1442-1447). Date of Publication: 3 Jun 2018	Purpose: To describe the association between breastfeeding and postpartum depressive symptoms among a sample of adolescent and young adult mothers and to determine whether breastfeeding difficulty moderates this association. Materials and methods: Data were derived from a prospective cohord or pregnant adolescent and young adult mothers (ages 14-21 as they transitioned to parenthood. This analysis uses data collected during pregnancy and a 6 nonths postpartum among mothers (a = 157) who initiated breastfeeding difficulty and be transitioned breastfeeding difficulty associated by a stransition. Barby transitioned comparison was used to adjust for prenatal depressive symptoms and other potential confounders. Results: Postpartum thepressive symptoms were not significantly associated with breastfeeding difficulty and breastfeeding at 6 months, those who reported no early breastfeeding difficulties had the lowest depressive scores and those who reported much early breastfeeding difficulty had the highest depressive scores at 6 months. Conclusions: Minimizing challenges with breastfeeding may help improve postpartum mental head to appropriate professional breastfeeding and more providers bloud help young pregnant women manage expectations about breastfeeding and ensure that they are linked to appropriate professional breastfeeding support during the early postpartum period.	) KW	HE	0	×	×

# PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Title [.]			
Identification	1a	Identify the report as a protocol of a systematic review	P. 1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	N/A
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	P.3
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	P.1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	P. 10
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	N/A
Support:			
Sources	5a	Indicate sources of financial or other support for the review	N/A
Sponsor	5b	Provide name for the review funder and/or sponsor	P. 10
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	P. 10
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	P. 5-6
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	P. 6
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	P. 6-7
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	P. 7
	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it	P. 7-8 Appendix 1

2	
3	
4	
5	
6	
7	
/ 0	
0	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
27	
20	
38	
39	
40	
41	
42	
43	
44	
45	
46	

1

Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	P. 7-8
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	P. 7-8
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	P. 7-8
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	P. 7-8
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	P. 7-8
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	P. 8
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	P. 9
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as $I^2$ , Kendall's $\tau$ )	P. 9
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	P. 9
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	N/A
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	P. 9
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	N/A

* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.